[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 146
1. Ahmed N, Salman M, Mansoor MA: Gorlin-goltz syndrome. J Coll Physicians Surg Pak; 2007 Sep;17(9):568-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple jaw cysts are a characteristic manifestation of basal cell nevus (Gorlin) syndrome.
  • In 90% of the patients, nevoid basal cell carcinoma syndrome is associated with recurring odontogenic keratocysts.
  • This patient showed recurrent jaw and maxillary cysts, for which he was followed for 2 years.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903410.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


2. Metze K, Bedin V, Adam RL, Macedo de Souza E, Cintra ML: 'Recurrent' basal cell carcinomas may represent new primary neoplasias: differences between aggressive and nonaggressive histologic subtypes. J Plast Reconstr Aesthet Surg; 2007;60(4):451-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Recurrent' basal cell carcinomas may represent new primary neoplasias: differences between aggressive and nonaggressive histologic subtypes.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Br J Plast Surg. 2005 Sep;58(6):795-805 [16086990.001]
  • (PMID = 17349608.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


3. Huang CY, Feng CH, Hsiao YC, Chuang SS, Yang JY: Burn scar carcinoma. J Dermatolog Treat; 2010 Nov;21(6):350-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burn scar carcinoma.
  • INTRODUCTION: Since Jean-Nicolas Marjolin reported carcinoma arising in post-traumatic scars in 1828, the term 'Marjolin ulcer' has been applied to malignant changes in burn scars.
  • METHODS: From 1989 to 2008, there were 11 cases noted as burn scar carcinoma in Chang Gung Memorial Hospital.
  • Ten were reported as squamous cell carcinoma (SCC) and the one was verrucous carcinoma.
  • One patient received above-knee amputation and adjuvant therapy because recurrent verrucous carcinoma occurred 2 years later.
  • Most scar malignancies are SCC while other cell types are rarer.
  • CONCLUSION: The casual association between burn injuries and a later risk of basal cell carcinoma is questionable.
  • Owing to poor prognosis in advanced scar cancer, the best treatment for scar carcinoma is to prevent the scar from developing repeated ulceration by performing aggressive initial burn wound care: early grafting by surgeons and daily scar care with regular follow-up for patients.
  • [MeSH-major] Burns / complications. Carcinoma, Squamous Cell / surgery. Carcinoma, Verrucous / surgery. Cicatrix / complications. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Scars.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20438387.001).
  • [ISSN] 1471-1753
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Pereira PR, Odashiro AN, Rodrigues-Reyes AA, Correa ZM, de Souza Filho JP, Burnier MN Jr: Histopathological review of sebaceous carcinoma of the eyelid. J Cutan Pathol; 2005 Aug;32(7):496-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological review of sebaceous carcinoma of the eyelid.
  • BACKGROUND: Sebaceous carcinoma of the eyelid can clinically mimic benign conditions, such as recurrent chalazion and inflammation and histopathologically squamous cell and basal cell carcinoma (BCC).
  • This retrospective study was undertaken as an attempt to improve the characterization and consequently the diagnosis of these tumors.
  • METHODS: Retrospective analysis was performed on eyelid specimens diagnosed as sebaceous carcinoma retrieved from Henry C.
  • Of these, 75% had features similar to squamous cell carcinoma (SqCC), some with dyskeratosis (30%) and 7% resembled BCC.
  • CONCLUSION: Sebaceous carcinoma presented as a poorly differentiated lesion in most cases of this series, which suggests a possibility of misdiagnosis because of its similarities to SqCC.
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Chalazion / diagnosis. Diagnosis, Differential. Humans. Retrospective Studies. Single-Blind Method. Vacuoles / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008694.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


5. Kobayashi T, Maruyama S, Cheng J, Ida-Yonemochi H, Yagi M, Takagi R, Saku T: Histopathological varieties of oral carcinoma in situ: Diagnosis aided by immunohistochemistry dealing with the second basal cell layer as the proliferating center of oral mucosal epithelia. Pathol Int; 2010 Mar;60(3):156-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological varieties of oral carcinoma in situ: Diagnosis aided by immunohistochemistry dealing with the second basal cell layer as the proliferating center of oral mucosal epithelia.
  • To make reproducible diagnoses for oral carcinoma in situ (CIS), combined immunohistochemistry directed at the positioning of squamous cell proliferation (Ki-67) and differentiation (keratin (K) 13 and K19) was used, both of which support histological evaluations by providing biological evidence.
  • Normal/hyperplastic epithelia was defined by K19+ cells only in the first basal layer, K13+ cells in the third basal and upper layers, and sporadic Ki-67+ cells in the second basal layer.
  • These profiles indicated that a proliferating center of the oral epithelium is located in the parabasal cell layer, and K19 and K13 can be regarded as markers for basal and prickle cells, respectively.
  • When the definition was applied, surgical margins in 172 recurrent cases were shown to contain CIS (39.4%) and squamous cell carcinoma (55.8%), indicating that the new diagnostic criteria for CIS reflected clinical behaviors of the cases.
  • [MeSH-major] Carcinoma in Situ / metabolism. Cell Proliferation. Mouth Mucosa / metabolism. Mouth Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20403041.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


6. Ong LY, Lane CM: Eyelid contracture may indicate recurrent basal cell carcinoma, even after Mohs' micrographic surgery. Orbit; 2009;28(1):29-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid contracture may indicate recurrent basal cell carcinoma, even after Mohs' micrographic surgery.
  • Mohs' micrographic surgery (MMS) is an effective means of margin control in the management of periocular basal cell carcinomas (BCC).
  • We describe three cases of recurrent BCC that presented with progressive eyelid contracture after MMS.
  • Careful long-term surveillance with serial photography may identify early eyelid contracture and thus assist in the detection of recurrent BCC after MMS and improve patient outcome.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Contracture / pathology. Eyelid Neoplasms / surgery. Mohs Surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19229742.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Soysal HG, Soysal E, Markoç F, Ardiç F: Basal cell carcinoma of the eyelids and periorbital region in a Turkish population. Ophthal Plast Reconstr Surg; 2008 May-Jun;24(3):201-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the eyelids and periorbital region in a Turkish population.
  • PURPOSE: To review the clinical and histopathologic features, treatment, and outcomes of eyelid basal cell carcinomas.
  • METHODS: The clinical records and histopathologic specimens of 311 patients with eyelid basal cell carcinomas were reviewed and analyzed retrospectively.
  • The most common histologic subtypes were infiltrative, nodular, and basosquamous basal cell carcinomas.
  • Nearly one-third (29.9%) of the patients were previously recurrent.
  • Recurrent basal cell carcinomas were larger, with longer duration of lesion and a higher rate of orbital and perineural invasion.
  • Basosquamous basal cell carcinomas were more likely to have prior recurrences, larger lesion size, and the highest rate of orbital invasion.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520835.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Yu HS, Liao WT, Chai CY: Arsenic carcinogenesis in the skin. J Biomed Sci; 2006 Sep;13(5):657-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common arsenic-induced skin cancers are Bowen's disease (carcinoma in situ), basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • Arsenic exposure is associated with G2/M cell cycle arrest and DNA aneuploidy in both cultured keratinocytes and As-BD lesions.
  • The multiple and recurrent skin lesions are associated with cellular immune dysfunction in chronic arsenism.
  • Since CD4+ cells are the target cell affected by As, the interaction between CD4+ cells and epidermal keratinocytes under As affection might be closely linked to the pathogenesis of multiple occurrence of arsenic-induced skin cancer.

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807664.001).
  • [ISSN] 1021-7770
  • [Journal-full-title] Journal of biomedical science
  • [ISO-abbreviation] J. Biomed. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; 0 / Transcription Factors; N712M78A8G / Arsenic
  • [Number-of-references] 110
  •  go-up   go-down


9. Perkins W: Who should have Mohs micrographic surgery? Curr Opin Otolaryngol Head Neck Surg; 2010 Aug;18(4):283-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: There is increasing evidence to support the use of Mohs micrographic surgery in the treatment of recurrent and primary basal cell carcinoma and in squamous cell carcinoma, particularly when there is evidence of perineural invasion.
  • [MeSH-minor] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Decision Making. Dermatofibrosarcoma / surgery. Histiocytoma, Benign Fibrous / surgery. Humans. Melanoma / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20613530.001).
  • [ISSN] 1531-6998
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


10. Raasch B, Woolley T: Management of primary superficial basal cell carcinoma. Aust Fam Physician; 2006 Jun;35(6):455-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of primary superficial basal cell carcinoma.
  • BACKGROUND: Superficial basal cell carcinoma (SBCC) is a skin cancer commonly treated by general practitioners.
  • Areas of educational need were identified with respect to management of inadequately treated or recurrent lesions.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Subcutaneous Tissue

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16751865.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


11. Leibovitch I, Huilgol SC, Richards S, Paver R, Selva D: Scalp tumors treated with Mohs micrographic surgery: clinical features and surgical outcome. Dermatol Surg; 2006 Nov;32(11):1369-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common tumors were basal cell carcinoma (BCC), 57.9%; squamous cell carcinoma (SCC), 35.8%; Bowen's disease (BD), 4.1%; and atypical fibroxanthoma (AFX), 1.6%.
  • Recurrent tumors comprised 37% of cases.
  • [MeSH-major] Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / surgery. Scalp. Skin Neoplasms / epidemiology. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Australia / epidemiology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Mohs Surgery. Prospective Studies. Treatment Outcome


12. Dumont T, Simon E, Garnier B, Sellal S, Stricker M, Chassagne JF: [Contribution of the pathology examination in the operating theatre in patients with skin cancer: retrospective analysis of 388 patients]. Rev Stomatol Chir Maxillofac; 2006 Apr;107(2):75-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Intérêt de l'examen histologique extemporané dans les carcinomes cutanés: étude rétrospective de 388 patients.
  • MATERIAL AND METHOD: The study population included 388 patients, mean age 69.5 years (28-98 years) who underwent resection of 544 skin tumors (520 primary and 36 recurrent), 76.6% unique tumors.
  • Recurrent tumors (5.0% of resections) accounted for 27% of the positive pathological results.
  • [MeSH-major] Carcinoma / surgery. Microsurgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / pathology. Eyelid Neoplasms / surgery. False Negative Reactions. Female. Humans. Male. Middle Aged. Mohs Surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Nose Neoplasms / pathology. Nose Neoplasms / surgery. Operating Rooms. Reoperation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16738511.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


13. Chai L, Tang J: [Analysis of 41 cases of basal cell carcinoma in maxillofacial area]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Apr;20(7):297-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 41 cases of basal cell carcinoma in maxillofacial area].
  • OBJECTIVE: To explore the incidence, location and relationship between surgical margin and metastasis of basal cell carcinoma (BCC) in maxillofacial area.
  • Of all the 41 patients, 4 patients were found to suffer regional lymph nodes metastasis or local bone destruction at the first visit (9.8%), 3 patients (7.3%) had a recurrent BCC.
  • [MeSH-major] Carcinoma, Basal Cell. Facial Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780141.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Siddiqui F, Patel M, Khan M, McLean S, Dragovic J, Jin JY, Movsas B, Ryu S: Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1047-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region.
  • METHODS AND MATERIALS: Patients with pathologically proven malignant lesions in the head-and-neck region were treated using single-dose SBRT (S-SBRT) or fractionated SBRT (F-SBRT).
  • There were three groups of patients: those with primary (n = 10), recurrent (n = 21), and metastatic tumors (n = 13).
  • The predominant histologic type was squamous cell carcinoma (n = 33).
  • Tumor control rates at 1 year were 83.3% and 60.6% in the primary and recurrent groups, respectively.
  • Median overall survival was 28.7, 6.7, and 5.6 months for the primary, recurrent, and metastatic groups, respectively.
  • CONCLUSIONS: The SBRT in single or fractionated doses offers a viable treatment option for selected patients with primary, recurrent, and metastatic head-and-neck cancers with functional preservation.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Radiosurgery / methods

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19327895.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kimball KJ, Straughn JM, Conner MG, Kirby TO: Recurrent basosquamous cell carcinoma of the vulva. Gynecol Oncol; 2006 Aug;102(2):400-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent basosquamous cell carcinoma of the vulva.
  • BACKGROUND: Basosquamous cell carcinoma (BSC) of the vulva is a rare entity with interesting prognostic and therapeutic implications.
  • CASE: A case of recurrent BSC of the vulva treated with unilateral radical vulvectomy and unilateral lymph node dissection is reported.
  • CONCLUSION: BSC is a rare disorder of the vulva.
  • The metastatic potential of this tumor is not fully understood, but likely is intermediate between squamous cell carcinoma and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Carcinoma, Basosquamous / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Vulvar Neoplasms / pathology. Vulvar Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16624392.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Tschen EH, Wong DS, Pariser DM, Dunlap FE, Houlihan A, Ferdon MB, Phase IV ALA-PDT Actinic Keratosis Study Group: Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol; 2006 Dec;155(6):1262-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AKs are believed to progress to in situ squamous cell carcinoma (SCC) and potentially, to invasive SCC.
  • Of the 162 recurrent lesions 16 were lost to follow up, seven spontaneously cleared and 139 were biopsied.
  • With respect to the lesions biopsied, 91% (127/139) were diagnosed histopathologically as AK, with the balance of lesions being SCC (nine of 139: 7%), basal cell carcinoma (one of 139: 0.7%) and other non-AK diagnoses (two of 139: 1%).
  • The clinical diagnosis of AK by investigators appeared to be accurate, with 91% (200/220) of the untreated clinically diagnosed AK lesions being histopathologically confirmed to be AK (AK, 142/220: 65%; advanced AK, 29/220: 13%; macular AK, 29/220: 13%).


17. Chen WL, Li JS, Yang ZH, Huang ZQ, Wang JU, Zhang B: Two submental island flaps for reconstructing oral and maxillofacial defects following cancer ablation. J Oral Maxillofac Surg; 2008 Jun;66(6):1145-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary lesions included squamous cell carcinoma of the tongue (8 cases), buccal mucosa (16), floor of the mouth (4), lower gingiva (3), oropharynx (2); recurrent squamous cell carcinoma of the palate (3); and basal cell carcinoma of the facial skin (2).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Face / blood supply. Fatal Outcome. Female. Humans. Male. Middle Aged. Neck / blood supply. Neck / surgery. Neoplasm Staging. Oral Surgical Procedures / methods. Reconstructive Surgical Procedures / methods. Retrospective Studies

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486779.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Veness MJ: High-risk cutaneous squamous cell carcinoma of the head and neck. J Biomed Biotechnol; 2007;2007(3):80572
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-risk cutaneous squamous cell carcinoma of the head and neck.
  • Nonmelanoma skin cancers (squamous cell and basal cell carcinomas) occur at an epidemic rate in many countries with the worldwide incidence increasing.
  • The sun-exposed head and neck are the most frequent sites for these cancers to arise and in most patients diagnosed with a cutaneous squamous cell carcinoma, local treatment is usually curative.
  • However, a subset is diagnosed with a high-risk cutaneous squamous cell carcinoma.
  • High-risk factors include size (>2 cm), thickness/depth of invasion (>4 mm), recurrent lesions, the presence of perineural invasion, location near the parotid gland, and immunosuppression.
  • Despite treatment, many patients developing metastatic cutaneous squamous cell carcinoma experience mortality and morbidity usually as a consequence of uncontrolled metastatic nodal disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 2005 Sep;115(9):1561-7 [16148695.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 May;124(5):582-7 [9604987.001]
  • [Cites] Dermatol Surg. 2000 Mar;26(3):289-92 [10759812.001]
  • [Cites] Br J Dermatol. 2002 Jan;146(1):18-25 [11841362.001]
  • [Cites] Dermatol Surg. 2002 Mar;28(3):268-73 [11896781.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 May;128(5):521-6 [12003582.001]
  • [Cites] Int J Oral Maxillofac Surg. 2002 Apr;31(2):154-7 [12102412.001]
  • [Cites] Arch Dermatol. 2003 Mar;139(3):301-6 [12622621.001]
  • [Cites] Plast Reconstr Surg. 2003 Jul;112(1):57-63 [12832877.001]
  • [Cites] J Am Acad Dermatol. 1992 Aug;27(2 Pt 1):241-8 [1430364.001]
  • [Cites] Head Neck. 2003 Dec;25(12):1027-33 [14648861.001]
  • [Cites] Oral Oncol. 2004 Jan;40(1):92-8 [14662421.001]
  • [Cites] Oral Oncol. 2004 Feb;40(2):223-7 [14693248.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):651-5 [15061850.001]
  • [Cites] Semin Cutan Med Surg. 2004 Sep;23(3):167-73 [15584682.001]
  • [Cites] J Am Acad Dermatol. 2005 Jan;52(1):101-8 [15627087.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Jul;131(7):551-5 [16027274.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):976-90 [1607418.001]
  • [Cites] Australas Radiol. 2005 Oct;49(5):365-76 [16174174.001]
  • [Cites] J Am Acad Dermatol. 2005 Dec;53(6):1067-71 [16310071.001]
  • [Cites] Head Neck. 2006 Mar;28(3):244-8 [16395715.001]
  • [Cites] Med J Aust. 2006 Jan 2;184(1):6-10 [16398622.001]
  • [Cites] J Cutan Pathol. 2006 Apr;33(4):261-79 [16630176.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2389-96 [16649220.001]
  • [Cites] Ann Surg Oncol. 2006 Jul;13(7):902-9 [16788750.001]
  • [Cites] Dermatol Surg. 2006 Sep;32(9):1163-70 [16970698.001]
  • [Cites] Dermatol Surg. 2006 Nov;32(11):1309-21 [17083582.001]
  • [Cites] Am J Clin Pathol. 1990 Nov;94(5):624-7 [2239827.001]
  • [Cites] Head Neck. 1989 May-Jun;11(3):264-8 [2722504.001]
  • [Cites] Hum Pathol. 1986 Apr;17(4):346-54 [3957335.001]
  • [Cites] Head Neck Surg. 1980 May-Jun;2(5):361-5 [7364589.001]
  • [Cites] Dermatology. 1994;189(1):52-4 [8003787.001]
  • [Cites] J Am Acad Dermatol. 1993 Apr;28(4):628-31 [8463466.001]
  • [Cites] Laryngoscope. 1996 Feb;106(2 Pt 1):156-8 [8583845.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):915-9 [9041153.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1758-64 [10223570.001]
  • (PMID = 17541471.001).
  • [ISSN] 1110-7243
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1874675
  •  go-up   go-down


19. Simeonov R, Simeonova G: Comparative morphometric analysis of recurrent and nonrecurrent canine basal cell carcinomas: a preliminary report. Vet Clin Pathol; 2010 Mar;39(1):96-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative morphometric analysis of recurrent and nonrecurrent canine basal cell carcinomas: a preliminary report.
  • BACKGROUND: Most reports of canine basal cell carcinomas (BCCs) focus on morphologic appearance rather than biologic behavior.
  • The dogs were monitored by their owners over a period of 60 weeks to detect local recurrence of the tumor; recurrent tumors were confirmed histologically.
  • RESULTS: Six nonrecurrent and 5 recurrent tumors were analyzed.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vet Clin Pathol. 2010 Jun;39(2):133; author reply 133-4 [20624263.001]
  • (PMID = 19645743.001).
  • [ISSN] 1939-165X
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Pérez de la Fuente T, González González I: Recurrent basal cell carcinoma of the lower limb with tibial invasion. J Cutan Med Surg; 2006 Jan-Feb;10(1):36-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent basal cell carcinoma of the lower limb with tibial invasion.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common skin malignancy and is most prevalent on the head and neck region, although BCC can occur in other sites, including the lower limbs.
  • OBJECTIVE: We report the case of an 85-year-old female patient who experienced recurrent BCCs in the lower limb with tibial invasion.
  • [MeSH-major] Bone Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology. Tibia
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Imaging, Three-Dimensional. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241571.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Heppt W: [Skin tumors in facial plastic surgery]. HNO; 2009 Apr;57(4):324-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common histologic findings are actinic keratosis and basal cell carcinoma.
  • In patients with recurrent or deeply infiltrative tumors, reconstructive procedures of the facial nerve, parotid duct, and lacrimal duct might be needed.
  • [MeSH-major] Facial Neoplasms / diagnosis. Facial Neoplasms / surgery. Otorhinolaryngologic Surgical Procedures / trends. Reconstructive Surgical Procedures / trends. Skin Neoplasms / diagnosis. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Feb;99(2):136-41 [15660081.001]
  • [Cites] Laryngoscope. 1990 Mar;100(3):313-9 [2308457.001]
  • [Cites] HNO. 1998 Jun;46(6):569-78 [9677488.001]
  • [Cites] Plast Reconstr Surg. 2008 Jul;122(1):240-3 [18594411.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Dec;4(12):1080-4 [17176417.001]
  • [Cites] HNO. 2007 Jun;55(6):497-510 [17486306.001]
  • [Cites] Klin Monbl Augenheilkd. 1988 Dec;193(6):647-50 [3065572.001]
  • [Cites] Plast Reconstr Surg. 1967 May;39(5):472-7 [5336914.001]
  • [Cites] Plast Reconstr Surg. 2007 Oct;120(5):1171-207; discussion 1208-16 [17898591.001]
  • [Cites] Klin Monbl Augenheilkd. 2004 Aug;221(8):609-14 [15343443.001]
  • [Cites] Br J Plast Surg. 1962 Jul;15:242-54 [13871292.001]
  • [Cites] Adv Exp Med Biol. 2008;624:89-103 [18348450.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):144-8 [9754642.001]
  • [Cites] Plast Reconstr Surg. 2008 Feb;121(2):458-65 [18300962.001]
  • [Cites] GMS Curr Top Otorhinolaryngol Head Neck Surg. 2007;6:Doc02 [22073078.001]
  • [Cites] Dermatol Surg. 2000 Mar;26(3):215-8 [10759796.001]
  • [Cites] Langenbecks Arch Surg. 2000 Jul;385(4):284-9 [10958513.001]
  • (PMID = 19347378.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


22. Yang QS, Gu JL, Du LQ, Jia LL, Qin LL, Wang Y, Fan FY: ShRNA-mediated Ku80 gene silencing inhibits cell proliferation and sensitizes to gamma-radiation and mitomycin C-induced apoptosis in esophageal squamous cell carcinoma lines. J Radiat Res; 2008 Jul;49(4):399-407
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ShRNA-mediated Ku80 gene silencing inhibits cell proliferation and sensitizes to gamma-radiation and mitomycin C-induced apoptosis in esophageal squamous cell carcinoma lines.
  • To investigate the effects of Ku80 depletion on cell growth and sensitization to gamma-radiation and MMC-induced apoptosis in esophageal squamous cell carcinoma lines.
  • Six human carcinoma cell lines (LNcaP, K562, MDA-MB-231, MCF-7, EC9706, and K150) and normal HEK293 cell line were examined for basal levels of Ku80 protein by western blotting analysis.
  • Cell proliferation was determined with MTT assay and colony formation assay and tumorigenicity in a xenograft model in vitro and in vivo.
  • The cell cycle distribution was determined by Flow cytometry.
  • Ku80 showed higher basal levels in six carcinoma cell lines than in HEK293.
  • Hence Ku80 may serve as a promising therapeutic target, particularly for recurrent esophageal tumors.
  • [MeSH-major] Antigens, Nuclear / metabolism. Apoptosis / drug effects. Apoptosis / radiation effects. Carcinoma, Squamous Cell / metabolism. Cell Proliferation / drug effects. Cell Proliferation / radiation effects. DNA-Binding Proteins / metabolism. Esophageal Neoplasms / metabolism. Mitomycin / administration & dosage
  • [MeSH-minor] Cell Line, Tumor. Gamma Rays. Gene Silencing. Humans. RNA, Small Interfering / genetics. Radiation Tolerance / drug effects. Radiation Tolerance / radiation effects

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18403903.001).
  • [ISSN] 0449-3060
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / DNA-Binding Proteins; 0 / Ku autoantigen; 0 / RNA, Small Interfering; 50SG953SK6 / Mitomycin
  •  go-up   go-down


23. Leibovitch I, Huilgol SC, Selva D, Lun K, Richards S, Paver R: Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery. J Am Acad Dermatol; 2005 Feb;52(2):295-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery.
  • BACKGROUND: Microcystic adnexal carcinoma (MAC) is reported to have a high rate of recurrence with standard wide local excision.
  • In 31.8% of cases it was a recurrent tumor.
  • In 32.5% of cases the tumor was initially misdiagnosed as basal cell carcinoma or squamous cell carcinoma.
  • Perineural invasion was recorded in 17.5% of cases; most of them (85.7%) were previously recurrent tumors.
  • [MeSH-major] Carcinoma, Skin Appendage / surgery. Mohs Surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Australia / epidemiology. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Child. Databases, Factual. Diagnostic Errors. Female. Follow-Up Studies. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prospective Studies. Retrospective Studies. Treatment Outcome


24. Yang Z, Sui Y, Xiong S, Liour SS, Phillips AC, Ko L: Switched alternative splicing of oncogene CoAA during embryonal carcinoma stem cell differentiation. Nucleic Acids Res; 2007;35(6):1919-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Switched alternative splicing of oncogene CoAA during embryonal carcinoma stem cell differentiation.
  • During retinoic-acid-induced P19 stem cell differentiation, the expression of CoAA undergoes a rapid switch to its dominant negative splice variant CoAM in the cavity of the embryoid body.
  • Using a CoAA minigene cassette, we find that the switched alternative splicing of CoAA and CoAM is regulated by the cis-regulating sequence upstream of the CoAA basal promoter.
  • We have previously shown that the CoAA gene is amplified in human cancers with a recurrent loss of this cis-regulating sequence.
  • These results together suggest that the upstream regulatory sequence contributes to alternative splicing of the CoAA gene during stem cell differentiation, and its selective loss in human cancers potentially deregulates CoAA alternative splicing and alters stem cell differentiation.
  • [MeSH-minor] Amino Acid Sequence. Animals. Base Sequence. Carcinoma, Embryonal / genetics. Carcinoma, Embryonal / metabolism. Cell Differentiation. Cell Line, Tumor. DNA-Binding Proteins / biosynthesis. Gene Expression Regulation, Developmental. High Mobility Group Proteins / biosynthesis. Mice. Molecular Sequence Data. Nuclear Matrix-Associated Proteins / metabolism. RNA-Binding Proteins / metabolism. Regulatory Elements, Transcriptional. SOXD Transcription Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2002 Oct 11;298(5592):416-9 [12376702.001]
  • [Cites] RNA. 2002 Sep;8(9):1102-11 [12358429.001]
  • [Cites] EMBO J. 2003 Mar 17;22(6):1359-69 [12628928.001]
  • [Cites] Cardiovasc Res. 2003 May 1;58(2):292-302 [12757864.001]
  • [Cites] J Cell Biol. 1982 Aug;94(2):253-62 [7107698.001]
  • [Cites] Annu Rev Genet. 1989;23:527-77 [2694943.001]
  • [Cites] Nature. 1990 Mar 29;344(6265):435-9 [1690859.001]
  • [Cites] Mol Cell Biol. 1993 Nov;13(11):6742-51 [7692231.001]
  • [Cites] Trends Biochem Sci. 1995 Jun;20(6):235-40 [7543225.001]
  • [Cites] Development. 1999 Feb;126(3):535-46 [9876182.001]
  • [Cites] Cell. 1999 Feb 5;96(3):307-10 [10025395.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 15;27(6):1409-20 [10037800.001]
  • [Cites] Mol Genet Metab. 1999 Jul;67(3):183-93 [10381326.001]
  • [Cites] Curr Opin Cell Biol. 1999 Jun;11(3):363-71 [10395553.001]
  • [Cites] Cell Biol Int. 2004;28(11):791-9 [15563401.001]
  • [Cites] J Cell Sci. 2004 Dec 15;117(Pt 26):6261-3 [15591240.001]
  • [Cites] J Cell Biochem. 2005 Feb 1;94(2):257-65 [15546139.001]
  • [Cites] Trends Mol Med. 2005 Jan;11(1):5-9 [15649816.001]
  • [Cites] Gene. 2005 Jan 3;344:1-20 [15656968.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Apr;42(4):342-57 [15648050.001]
  • [Cites] FEBS J. 2005 May;272(9):2118-31 [15853797.001]
  • [Cites] Curr Opin Cell Biol. 2005 Jun;17(3):262-8 [15901495.001]
  • [Cites] J Biol Chem. 2005 Jun 3;280(22):21022-8 [15793308.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 May;6(5):386-98 [15956978.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(13):5307-16 [15964789.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(15):6734-46 [16024807.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(16):6912-20 [16055705.001]
  • [Cites] Trends Biochem Sci. 2005 Sep;30(9):515-21 [16023350.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14290-5 [16183747.001]
  • [Cites] Glia. 2006 Jan 1;53(1):43-56 [16158417.001]
  • [Cites] RNA. 2006 Jan;12(1):111-21 [16373496.001]
  • [Cites] Cell Cycle. 2006 Feb;5(4):347-51 [16479168.001]
  • [Cites] Nat Cell Biol. 2006 Jul;8(7):756-63 [16767080.001]
  • [Cites] Oncogene. 2007 Feb 8;26(6):822-35 [16878147.001]
  • [Cites] Gene. 1999 Nov 1;239(2):341-9 [10548736.001]
  • [Cites] Cell. 2003 May 30;113(5):551-2 [12787492.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Sep;67(3):343-59, table of contents [12966139.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):42750-60 [12917399.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(1):442-53 [14673176.001]
  • [Cites] FEBS Lett. 2004 Feb 27;560(1-3):192-8 [14988021.001]
  • [Cites] EMBO J. 2004 Apr 21;23(8):1834-44 [15057274.001]
  • [Cites] EMBO J. 2004 Apr 21;23(8):1782-91 [15057275.001]
  • [Cites] RNA. 2004 Oct;10(10):1489-98 [15383674.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6212-7 [10823961.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(4):1285-96 [11158314.001]
  • [Cites] J Biol Chem. 2001 Sep 7;276(36):33375-83 [11443112.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):92-7 [11689953.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):13-9 [11753382.001]
  • [Cites] Curr Biol. 2002 Jan 8;12(1):1-11 [11790298.001]
  • [Cites] Curr Biol. 2002 Jan 8;12(1):13-25 [11790299.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1146-51 [11818535.001]
  • [Cites] Cell. 2002 Feb 22;108(4):501-12 [11909521.001]
  • [Cites] Nat Rev Genet. 2002 May;3(5):370-9 [11988762.001]
  • [Cites] Curr Opin Genet Dev. 2002 Aug;12(4):441-6 [12100890.001]
  • [Cites] Dev Cell. 2002 Aug;3(2):167-70 [12194848.001]
  • [Cites] FEBS Lett. 2002 Nov 6;531(2):109-14 [12417296.001]
  • (PMID = 17337438.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ DQ294957
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CoAA protein, mouse; 0 / DNA-Binding Proteins; 0 / High Mobility Group Proteins; 0 / Nuclear Matrix-Associated Proteins; 0 / Oncogene Proteins; 0 / PTB-associated splicing factor; 0 / RNA-Binding Proteins; 0 / SOXD Transcription Factors; 0 / Sox6 protein, mouse; 0 / Transcription Factors; 0 / p54nrb protein, mouse
  • [Other-IDs] NLM/ PMC1874587
  •  go-up   go-down


25. Narayana A, Cohen GN, Zaider M, Chan K, Lee N, Wong RJ, Boyle J, Shaha A, Kraus D, Shah J, Zelefsky MJ: High-dose-rate interstitial brachytherapy in recurrent and previously irradiated head and neck cancers--preliminary results. Brachytherapy; 2007 Apr-Jun;6(2):157-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose-rate interstitial brachytherapy in recurrent and previously irradiated head and neck cancers--preliminary results.
  • PURPOSE: Although high-dose-rate brachytherapy (HDRBT) offers significant advantages over low dose rate brachytherapy, there are scant data on improved local control (LC) and treatment-related complications in patients with recurrent head and neck (H&N) cancers.
  • We report our preliminary results in patients with recurrent H&N cancers treated with interstitial HDRBT.
  • METHODS AND MATERIALS: Thirty patients with recurrent H&N cancers were treated with HDRBT between September 2003 and October 2005.
  • CONCLUSION: The preliminary results of HDRBT indicate an acceptable LC and morbidity in recurrent H&N cancers.
  • Based on these encouraging results, prospective clinical trials are warranted using HDRBT in recurrent H&N cancers to decrease late toxicity.
  • [MeSH-major] Brachytherapy. Head and Neck Neoplasms / radiotherapy. Hemibody Irradiation. Neoplasm Recurrence, Local
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Female. Follow-Up Studies. Humans. Male. Melanoma / radiotherapy. Middle Aged. Radiation Injuries / etiology. Radiotherapy Dosage. Retrospective Studies. Sarcoma / radiotherapy. Survival Analysis. Time Factors. Treatment Outcome. Tumor Burden / radiation effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434110.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Ogunsalu C, Daisley H, Kamta A, Kanhai D, Mankee M, Maharaj A: Odontogenic keratocyst in Jamaica: a review of five new cases and five instances of recurrence together with comparative analyses of four treatment modalities. West Indian Med J; 2007 Jan;56(1):90-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A comparative analysis offour different treatment modalities used in the treatment of OKC in these patients (new and recurrent cases) is reported.
  • Of significance, one case of nevoid basal cell carcinoma syndrome (NBCCS) and a case of ameloblastomatous transformation in the wall of an OKC keratocyst were recorded The age range of the new cases was 12 to 44 years.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621852.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Jamaica
  •  go-up   go-down


27. Tan PY, Ek E, Su S, Giorlando F, Dieu T: Incomplete excision of squamous cell carcinoma of the skin: a prospective observational study. Plast Reconstr Surg; 2007 Sep 15;120(4):910-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incomplete excision of squamous cell carcinoma of the skin: a prospective observational study.
  • BACKGROUND: Squamous cell carcinoma is the second most common cancer of the skin.
  • It behaves differently from basal cell carcinoma.
  • Few large-scale studies have identified risk factors for incomplete excision of cutaneous squamous cell carcinoma.
  • METHODS: A total of 517 histopathologically confirmed squamous cell carcinomas were excised from January of 2001 to December of 2002 at the Peter MacCallum Cancer Institute.
  • Age (p = 0.61), sex (p = 0.075), tumor size (p = 0.521), surgeon's experience (p = 0.092), and recurrent lesions (p = 0.408) were not statistically significant risk factors.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Prospective Studies


28. Desai TD, Desai AD, Horowitz DC, Kartono F, Wahl T: The use of high-frequency ultrasound in the evaluation of superficial and nodular basal cell carcinomas. Dermatol Surg; 2007 Oct;33(10):1220-7; discussion 1226-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of high-frequency ultrasound in the evaluation of superficial and nodular basal cell carcinomas.
  • BACKGROUND: Frequencies of 20 MHz may be appropriate to visualize basal cell carcinomas (BCCs) including their tumor thickness and margins.
  • Morpheaform, recurrent BCCs, BCCs in areas difficult to scan, and BCCs with specific properties were excluded from this study.
  • It could be warranted if clinical or histologic diagnosis is uncertain.
  • [MeSH-major] Carcinoma, Basal Cell / ultrasonography. Skin Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903155.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Has C, Burger B, Volz A, Kohlhase J, Bruckner-Tuderman L, Itin P: Mild clinical phenotype of Kindler syndrome associated with late diagnosis and skin cancer. Dermatology; 2010;221(4):309-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mild clinical phenotype of Kindler syndrome associated with late diagnosis and skin cancer.
  • Kindler syndrome (KS) is a heritable skin disorder with a complex phenotype consisting of congenital skin blistering, photosensitivity, progressive generalized poikiloderma and extensive skin atrophy.
  • The diagnosis was established in their seventh and eighth decades of life, and confirmed by mutation analysis.
  • Both patients were homozygous for the recurrent FERMT1 mutation, c.328C→T, p.R110X.
  • Taken together, we describe the natural course of KS, the morphological abnormalities occurring in the skin of older KS patients, we discuss the differential diagnosis and the association between KS and squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Delayed Diagnosis. Neoplasms, Squamous Cell / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Basement Membrane / pathology. Blister / diagnosis. Blister / genetics. Blister / pathology. Blister / surgery. Cryosurgery. Epidermolysis Bullosa / diagnosis. Epidermolysis Bullosa / genetics. Epidermolysis Bullosa / pathology. Epidermolysis Bullosa / surgery. Female. Fluorouracil / therapeutic use. Homozygote. Humans. Male. Membrane Proteins / genetics. Middle Aged. Mutation. Neoplasm Proteins / genetics. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology. Periodontal Diseases / diagnosis. Periodontal Diseases / genetics. Periodontal Diseases / pathology. Periodontal Diseases / surgery. Photosensitivity Disorders / diagnosis. Photosensitivity Disorders / genetics. Photosensitivity Disorders / pathology. Photosensitivity Disorders / surgery

  • Genetic Alliance. consumer health - Kindler syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20938162.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / FERMT1 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil; Poikiloderma of Kindler
  •  go-up   go-down


30. Ammann-Rauch D, Bumann J, Catalano E: Unspecific redness of the eyelid--two malignant tumours. Klin Monbl Augenheilkd; 2006 May;223(5):412-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unspecific redness of the eyelid--two malignant tumours.
  • Recurrent trichiasis and a slight ulceration had developed during the last year.
  • A superficial spreading melanoma 0.4 mm depth in the Breslow classification was detected and right next to it a superficial basal cell carcinoma.
  • CONCLUSION: Chronic redness at or around the lid margin which does not respond to therapy should be biopsied as malignant tumours may well be hidden behind it.
  • [MeSH-major] Eyelid Neoplasms / complications. Eyelid Neoplasms / surgery. Neoplasms, Multiple Primary / surgery. Pigmentation Disorders / diagnosis. Pigmentation Disorders / prevention & control. Skin Neoplasms / diagnosis. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Pigmentation Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16705518.001).
  • [ISSN] 0023-2165
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Gurgel CA, Ramos EA, Azevedo RA, Sarmento VA, da Silva Carvalho AM, dos Santos JN: Expression of Ki-67, p53 and p63 proteins in keratocyst odontogenic tumours: an immunohistochemical study. J Mol Histol; 2008 Jun;39(3):311-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No difference in the immunostaining for these proteins was observed between primary and recurrent KOTs (Ki-67: P = 0.5591; p53: P = 0.9847; p63: P = 0.9127), or between KOTs associated with Nevoid Basal Cell Carcinoma Syndrome (NBCCS) and sporadic KOTs (Ki-67: P = 0.7013; p53: P = 0.3197; p63: P = 0.2427).
  • In addition, p63 immunostaining may represent immaturity of keratinocytes in KOTs, and suggests that this protein may participate in the regulation of epithelial cell differentiation.
  • [MeSH-minor] Antibodies. Cell Count. Humans. Immunohistochemistry. Transcription Factors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 1989 Jan;92 ( Pt 1):123-30 [2674163.001]
  • [Cites] Histopathology. 2005 Dec;47(6):582-6 [16324195.001]
  • [Cites] J Clin Pathol. 1992 Nov;45(11):1007-10 [1452774.001]
  • [Cites] J Oral Pathol Med. 1995 Oct;24(9):393-7 [8537911.001]
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1099-105 [10594758.001]
  • [Cites] Nature. 1991 Jun 6;351(6326):453-6 [2046748.001]
  • [Cites] J Pathol. 1998 Apr;184(4):348-50 [9664899.001]
  • [Cites] J Endod. 2001 Jul;27(7):459-61 [11503996.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):323-31 [12076694.001]
  • [Cites] Oral Oncol. 2004 Nov;40(10):985-91 [15509489.001]
  • [Cites] Exp Cell Res. 2006 Apr 1;312(6):695-706 [16406339.001]
  • [Cites] Yonsei Med J. 2003 Oct 30;44(5):841-6 [14584101.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Jan;34(1):6-9 [11733180.001]
  • [Cites] J Oral Pathol Med. 1995 May;24(5):221-6 [7542341.001]
  • [Cites] Arch Pathol Lab Med. 2004 Mar;128(3):313-7 [14987156.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Feb;64(2):308-16 [16413905.001]
  • [Cites] J Pathol. 2002 Dec;198(4):417-27 [12434410.001]
  • [Cites] Cell. 2007 May 4;129(3):523-36 [17482546.001]
  • [Cites] Arch Oral Biol. 1995 Dec;40(12):1081-4 [8850645.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Sep;34(6):668-73 [16053892.001]
  • [Cites] Am J Pathol. 1991 Apr;138(4):867-73 [2012175.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Oral Oncol. 2002 Jul;38(5):407-15 [12110333.001]
  • [Cites] Histopathology. 1993 Apr;22(4):355-60 [8514278.001]
  • [Cites] J Contemp Dent Pract. 2000 Feb 15;1(2):60-74 [12167890.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] J Dent Res. 1999 Jul;78(7):1345-53 [10403462.001]
  • [Cites] Biochemistry (Mosc). 2005 Sep;70(9):955-71 [16266265.001]
  • [Cites] Regen Med. 2006 Jan;1(1):45-57 [17465819.001]
  • [Cites] J Oral Pathol Med. 2001 Aug;30(7):434-42 [11488422.001]
  • [Cites] Oral Dis. 2004 Jan;10(1):22-6 [14996290.001]
  • [Cites] J Oral Pathol Med. 2005 May;34(5):280-6 [15817071.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):342-6 [10873608.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):38-44 [16359856.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):90-5 [11818141.001]
  • [Cites] J Oral Pathol Med. 1996 May;25(5):249-55 [8835823.001]
  • [Cites] Curr Biol. 1992 Nov;2(11):581-3 [15336029.001]
  • [Cites] J Oral Pathol Med. 2006 Feb;35(2):75-80 [16430736.001]
  • [Cites] Oral Oncol. 2002 Apr;38(3):219-26 [11978543.001]
  • [Cites] Mol Cancer Res. 2006 Oct;4(10 ):759-68 [17050669.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1A):175-81 [16475695.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Jul;35(7):673-5 [16687239.001]
  • [Cites] Int J Oral Maxillofac Surg. 2001 Feb;30(1):14-25 [11289615.001]
  • [Cites] J Oral Pathol Med. 2000 Nov;29(10):477-82 [11048963.001]
  • (PMID = 18256893.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 0 / Ki-67 Antigen; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


32. Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale R, Sigal-Zafrani B, Longy M, Raynal V, Pierron G, de Mascarel I, Taris C, Stoppa-Lyonnet D, Pierga JY, Salmon R, Sastre-Garau X, Fourquet A, Delattre O, de Cremoux P, Aurias A: Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res; 2007;9(2):R24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity.
  • INTRODUCTION: Typical medullary breast carcinoma (MBC) has recently been recognized to be part of the basal-like carcinoma spectrum, a feature in agreement with the high rate of TP53 mutations previously reported in MBCs.
  • The present study was therefore designed to identify phenotypic and genetic alterations that distinguish MBCs from basal-like carcinomas (BLC).
  • CONCLUSION: Our study has revealed that MBCs are part of the basal-like group and share common genomic alterations with BLCs, the most frequent being 1q and 8q gains and X losses; however, MBCs are a distinct entity within the basal-like spectrum, characterized by a higher rate of KRT 5/6 expression, a higher rate of gains and losses than BLCs, recurrent 10p, 9p and 16q gains, 4p losses, and 1q, 8p, 10p and 12p amplicons.
  • Our results thus contribute to a better understanding of the heterogeneity in basal-like breast tumors and provide potential diagnostic tools.
  • [MeSH-major] Breast Neoplasms / classification. Breast Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Neoplasms, Basal Cell / classification. Neoplasms, Basal Cell / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biol Markers. 2003 Apr-Jun;18(2):99-105 [12841678.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):529-41 [17157792.001]
  • [Cites] Int J Surg Pathol. 2003 Jul;11(3):153-8 [12894346.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):499-507 [14760071.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):830-5 [14871808.001]
  • [Cites] J Pathol. 2004 Jun;203(2):661-71 [15141381.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):5988-97 [15447982.001]
  • [Cites] Cancer. 1977 Oct;40(4):1365-85 [907958.001]
  • [Cites] Radiother Oncol. 1987 Sep;10(1):1-6 [3671767.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):641-3 [10203285.001]
  • [Cites] Nature. 1999 Sep 16;401(6750):297-300 [10499591.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8534-40 [15574759.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8541-9 [15574760.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3413-22 [15381628.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):822-7 [15705879.001]
  • [Cites] Cancer Sci. 2005 Jun;96(6):333-9 [15958055.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1040-7 [15990007.001]
  • [Cites] Ann Neurol. 2005 Sep;58(3):483-7 [16130103.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7612-21 [16140926.001]
  • [Cites] Eur J Cancer. 2005 Oct;41(15):2304-11 [16140006.001]
  • [Cites] J Pathol. 2005 Nov;207(3):260-8 [16167361.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9727-34 [16266993.001]
  • [Cites] Mod Pathol. 2005 Dec;18(12):1623-31 [16258515.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8577-84 [16361540.001]
  • [Cites] Histopathology. 2000 Aug;37(2):175-81 [10931242.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7110-7 [12460933.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1991-6 [12466114.001]
  • [Cites] Histopathology. 2003 Apr;42(4):337-47 [12653945.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):628; author reply 628-9 [12697858.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):264-71 [16341146.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):195-207 [16341153.001]
  • [Cites] Cancer Cell. 2006 Feb;9(2):121-32 [16473279.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):424-8 [16497871.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4636-44 [16651414.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):779-82 [16740027.001]
  • [Cites] Bioinformatics. 2006 Jun 15;22(12):1540-2 [16595560.001]
  • [Cites] Histopathology. 2006 Jul;49(1):22-34 [16842243.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • (PMID = 17417968.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC1868916
  •  go-up   go-down


33. Hassanpour SE, Kalantar-Hormozi A, Motamed S, Moosavizadeh SM, Shahverdiani R: Basal cell carcinoma of scalp in patients with history of childhood therapeutic radiation: a retrospective study and comparison to nonirradiated patients. Ann Plast Surg; 2006 Nov;57(5):509-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of scalp in patients with history of childhood therapeutic radiation: a retrospective study and comparison to nonirradiated patients.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common human malignant neoplasm.
  • There was no meaningful difference in safe resection margin for the first lesion between the 2 groups (P = 0.27); however, the number of recurrent lesions was significantly higher in group A (P = 0.003).
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Basal Cell / surgery. Reconstructive Surgical Procedures / methods. Skin Neoplasms / radiotherapy. Skin Neoplasms / surgery. Survivors / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Plast Surg. 2007 May;58(5):589; author reply 589-90 [17452854.001]
  • (PMID = 17060730.001).
  • [ISSN] 0148-7043
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Vered M, Peleg O, Taicher S, Buchner A: The immunoprofile of odontogenic keratocyst (keratocystic odontogenic tumor) that includes expression of PTCH, SMO, GLI-1 and bcl-2 is similar to ameloblastoma but different from odontogenic cysts. J Oral Pathol Med; 2009 Aug;38(7):597-604
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aggressive biological behavior of odontogenic keratocysts (OKCs), unlike that of other odontogenic cysts, has argued for its recent re-classification as a neoplasm, 'keratocystic odontogenic tumor'.
  • Identification of mutations in the PTCH gene in some of the OKCs that were expected to produce truncated proteins, resulting in loss of control of the cell cycle, provided additional support for OKCs having a neoplastic nature.
  • METHODS: We investigated the immunohistochemical expression of the sonic hedgehog (SHH) signaling pathway-related proteins, PTCH, smoothened (SMO) and GLI-1, and of the SHH-induced bcl-2 oncoprotein in a series of primary OKC (pOKC), recurrent OKC (rOKC) and nevoid basal cell carcinoma syndrome-associated OKCs (NBCCS-OKCs), and compared them to solid ameloblastomas (SAMs), unicystic ameloblastomas (UAMs), 'orthokeratinized' OKCs (oOKCs), dentigerous cysts (DCs) and radicular cysts (RCs).
  • As OKCs vary considerably in their biologic behavior, it is suggested that the quality and quantity of interactions between the SHH and other cell cycle regulatory pathways are likely to work synergistically to define the individual phenotype and corresponding biological behavior of this lesion.
  • [MeSH-major] Hedgehog Proteins / metabolism. Jaw Neoplasms / metabolism. Odontogenic Cysts / metabolism. Receptors, Cell Surface / metabolism. Receptors, G-Protein-Coupled / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Ameloblastoma / immunology. Ameloblastoma / metabolism. Ameloblastoma / pathology. Analysis of Variance. Basal Cell Nevus Syndrome / immunology. Basal Cell Nevus Syndrome / metabolism. Basal Cell Nevus Syndrome / pathology. Case-Control Studies. Gene Expression Regulation, Neoplastic / physiology. Humans. Immunohistochemistry. Jaw Diseases / immunology. Jaw Diseases / metabolism. Jaw Diseases / pathology. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Reference Values. Second Messenger Systems / physiology. Signal Transduction / physiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473442.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / SMO protein, human; 0 / Transcription Factors; 0 / patched receptors
  •  go-up   go-down


35. Campbell RM, Barrall D, Wilkel C, Robinson-Bostom L, Dufresne RG Jr: Post-Mohs micrographic surgical margin tissue evaluation with permanent histopathologic sections. Dermatol Surg; 2005 Jun;31(6):655-8; discussion 658
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Incomplete resection of nonmelanoma skin cancer is associated with a relatively high rate of recurrent tumors.
  • RESULTS: Two excisions of nodular basal cell cancer were determined by the pathologist to have positive tumor involvement on post-Mohs permanent tissue.
  • On additional review, one specimen was interpreted to be more consistent with follicular epithelium, and the second was verified as a focus of nodular basal cell cancer.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Facial Neoplasms / surgery. Mohs Surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2006 Mar;32(3):463 [16640701.001]
  • (PMID = 15996415.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Kleydman Y, Manolidis S, Ratner D: Basal cell carcinoma with intracranial invasion. J Am Acad Dermatol; 2009 Jun;60(6):1045-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with intracranial invasion.
  • The risk of invasion and destruction of cranium, underlying dura, and cranial nerves by basal cell carcinoma (BCC) is extremely low, with an estimated incidence of 0.03%.
  • We describe a case of intracranial invasion of a multiply recurrent nasal BCC, which caused progressive bilateral blindness from optic nerve compression, with spinal canal involvement causing subsequent lower extremity weakness and paralysis.
  • This case underscores the importance of early and appropriate treatment of high risk BCC, and aggressive treatment of recurrent lesions as early as possible.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Nose Neoplasms / pathology. Orbit / pathology. Skull Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Blindness / etiology. Female. Humans. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467376.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Kyrgidis A, Vahtsevanos K, Tzellos TG, Xirou P, Kitikidou K, Antoniades K, Zouboulis CC, Triaridis S: Clinical, histological and demographic predictors for recurrence and second primary tumours of head and neck basal cell carcinoma. A 1062 patient-cohort study from a tertiary cancer referral hospital. Eur J Dermatol; 2010 May-Jun;20(3):276-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, histological and demographic predictors for recurrence and second primary tumours of head and neck basal cell carcinoma. A 1062 patient-cohort study from a tertiary cancer referral hospital.
  • Basal cell carcinoma (BCC) accounts for nearly 25% of all cancers in the human body and for almost 75% of skin malignancies; approximately 85% of basal cell carcinomas develop in the head and neck region.
  • Limited demographic, clinical and histological predictors for second primary and/or recurrent BCC have been identified to date.
  • We included 1062 patients with a histologically confirmed diagnosis of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Head and Neck Neoplasms / pathology. Hospitals, Special. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406722.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  •  go-up   go-down


38. Gudi V, Ormerod AD, Dawn G, Green C, MacKie RM, Douglas WS, Gupta G, Scottish Dermatological Society: Management of basal cell carcinoma by surveyed dermatologists in Scotland. Clin Exp Dermatol; 2006 Sep;31(5):648-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of basal cell carcinoma by surveyed dermatologists in Scotland.
  • BACKGROUND: The British Association of Dermatologists (BAD) has produced guidelines for management of basal cell carcinoma (BCC) in the UK.
  • A diagnostic biopsy was taken in 22% of lesions, and the rest were treated definitively after a clinical diagnosis of BCC, of which 90% were confirmed on histology.
  • Four of 21 recurrent tumours and 9 of 81 tumours on high-risk areas of the face were managed with curettage and cautery or cryotherapy, rather than surgical excision.
  • [MeSH-major] Carcinoma, Basal Cell. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16901303.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


39. Premalata CS, Kumar RV, Malathi M, Shenoy AM, Nanjundappa N: Cutaneous leiomyosarcoma, trichoblastoma, and syringocystadenoma papilliferum arising from nevus sebaceus. Int J Dermatol; 2007 Mar;46(3):306-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 54-year-old man presented with a recurrent swelling on the right occipital region of the scalp.
  • One was a well-circumscribed tumor located in the superficial dermis with lobules of basaloid cell aggregates with peripheral palisading and with no epidermal connection.
  • Unlike basal cell carcinoma, however, no cleft between the cellular aggregates and stroma was noted.
  • Foci of pigmentation were seen within cellular lobules and these features were consistent with a diagnosis of tricho-blastoma.
  • The third lesion was a spindle cell sarcoma which formed the major part of the lesion, diffusely infiltrating the dermis and subcutaneous tissue, elevating and ulcerating the overlying skin.
  • The wide excision specimen of the recurrent swelling consisted of a skin-covered nodule with ulceration, measuring 3 x 4 x 3 cm, with a gray-white whorled cut surface.
  • Multiple sections showed only spindle cell sarcoma infiltrating the skin and subcutaneous tissue, morphologically similar to the earlier tumor, with ulceration of the overlying skin.
  • Immunohistochemical stains on the spindle cell sarcoma showed positive staining for smooth muscle actin (SMA) (Fig.
  • Correlating the histomorphology and immunohistochemical findings, a diagnosis of cutaneous leiomyosarcoma with tricho-blastoma and syringocystadenoma papilliferum arising on nevus sebaceus was made.
  • The patient received postoperative radiotherapy and is disease free 8 months after diagnosis.


40. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R: Basal cell carcinoma treated with Mohs surgery in Australia III. Perineural invasion. J Am Acad Dermatol; 2005 Sep;53(3):458-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma treated with Mohs surgery in Australia III. Perineural invasion.
  • BACKGROUND: Perineural invasion (PNI) is an important factor may possibly influence the aggressiveness of basal cell carcinoma (BCC).
  • Most cases occurred in male patients (61%; P = .006) and in previously recurrent tumors (60.4%; P < .001).
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Peripheral Nerves / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Mohs Surgery. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Prospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112353.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


41. Chodorowski Z, Sein Anand J, Jassem J, Kopacz A, Kruszewski W, Emerich J, Senkus-Konefka E: [Late recurrence of malignant tumours 20 years after diagnosis and treatment]. Przegl Lek; 2007;64(4-5):372-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Late recurrence of malignant tumours 20 years after diagnosis and treatment].
  • Late recurrence of malignant tumours is very rare phenomenon.
  • Seven cases of late recurrent malignancy (melanoma--2 cases, clear cell renal cancer, stomach sarcoma, breast cancer, basal cell carcinoma, ovarian cancer) after 20-32 (average 22.3) years from diagnosis and treatment were described.
  • The histopathological examination results of primary and recurrent tumours were identical.
  • [MeSH-major] Neoplasm Recurrence, Local / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724919.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


42. Zghal M, Triki S, Elloumi-Jellouli A, Jbali A, Gargouri H, Benmously R, Souissi R, Chedly I, Brahim EB, Ayed MB, Fenniche S, Mokhtar I: [Contribution of the cryosurgery in the management of xeroderma pigmentosum]. Ann Dermatol Venereol; 2010 Oct;137(10):605-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] L'apport de la cryochirurgie dans la prise en charge du xeroderma pigmentosum.
  • BACKGROUND: Basal cell carcinoma (BCC) occurs frequently in young patients with xeroderma pigmentosum (XP).
  • Mean carcinoma size was 10mm.
  • We noted 10 cases of hypopigmentation (21.7%) and one notch on the nose following treatment for recurrent BCC on a radiotherapy scar.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Cryosurgery / methods. Facial Neoplasms / surgery. Head and Neck Neoplasms / surgery. Skin Neoplasms / surgery. Xeroderma Pigmentosum / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Reoperation. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Xeroderma pigmentosum.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Masson SAS.
  • (PMID = 20932439.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


43. Kyrgidis A, Tzellos TG, Vahtsevanos K, Triaridis S: New concepts for basal cell carcinoma. Demographic, clinical, histological risk factors, and biomarkers. A systematic review of evidence regarding risk for tumor development, susceptibility for second primary and recurrence. J Surg Res; 2010 Mar;159(1):545-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New concepts for basal cell carcinoma. Demographic, clinical, histological risk factors, and biomarkers. A systematic review of evidence regarding risk for tumor development, susceptibility for second primary and recurrence.
  • Basal cell carcinoma (BCC) is the commonest cancer in Caucasians and its incidence is increasing.
  • In addition, not enough information exists on the prognostic value of existing demographic and clinical risk predictors for BCC regarding development of second primary or recurrent tumors.
  • Conclusively, we suggest that further studies aimed in investigating second primary or recurrent BCC are needed to provide better information on the predictive value of certain demographic, clinical and histological factors.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Basal Cell / etiology. Neoplasm Recurrence, Local / epidemiology. Neoplasms, Second Primary / epidemiology. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19285687.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 86
  •  go-up   go-down


44. Chu CY, Cha ST, Chang CC, Hsiao CH, Tan CT, Lu YC, Jee SH, Kuo ML: Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1 alpha-directed invasion of human basal cell carcinoma cells. Oncogene; 2007 Apr 12;26(17):2491-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1 alpha-directed invasion of human basal cell carcinoma cells.
  • Basal cell carcinoma (BCC) is one of the most common skin neoplasms in humans and is usually characterized by local aggressiveness with little metastatic potential, although deep invasion, recurrence, and regional and distant metastases may occur.
  • We found that human BCC tissues and a BCC cell line had significant expression of CXCR4, which was higher in invasive than non-invasive BCC types.
  • Further, of 19 recurrent tumors among 390 BCCs diagnosed during the past 12 years, 17/19 (89.5%) had high CXCR4 expression.
  • We found that the CXCR4 ligand, stromal-cell-derived factor 1alpha (SDF-1alpha), directed BCC invasion and that this was mediated by time-dependent upregulation of mRNA expression and gelatinase activity of matrix metalloproteinase-13 (MMP-13).
  • [MeSH-major] Carcinoma, Basal Cell / enzymology. Carcinoma, Basal Cell / pathology. Chemokines, CXC / physiology. Matrix Metalloproteinase 13 / physiology
  • [MeSH-minor] Cell Line, Tumor. Chemokine CXCL12. Humans. Neoplasm Invasiveness. Receptors, CXCR4 / biosynthesis. Receptors, CXCR4 / genetics


45. Varga E, Kiss M, Szabó K, Kemény L: Detection of Merkel cell polyomavirus DNA in Merkel cell carcinomas. Br J Dermatol; 2009 Oct;161(4):930-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of Merkel cell polyomavirus DNA in Merkel cell carcinomas.
  • BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive tumour for which an increasing incidence has been reported.
  • A new human polyomavirus, Merkel cell polyomavirus (MCV), was recently isolated from these tumours by applying digital transcriptome subtraction methodology.
  • METHODS: Nine primary or recurrent MCCs from seven patients were examined; 29 other tumours (squamous cell, basal cell and basosquamous carcinomas and malignant melanomas) were examined for comparative purposes.
  • [MeSH-major] Antigens, Viral, Tumor / genetics. Capsid Proteins / genetics. Carcinoma, Merkel Cell / virology. Polyomaviridae / genetics. Polyomavirus Infections / virology. Skin Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438857.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor; 0 / Capsid Proteins
  •  go-up   go-down


46. Davari P, Hebert JL, Albertson DG, Huey B, Roy R, Mancianti ML, Horvai AE, McDaniel LD, Schultz RA, Epstein EH Jr: Loss of Blm enhances basal cell carcinoma and rhabdomyosarcoma tumorigenesis in Ptch1+/- mice. Carcinogenesis; 2010 Jun;31(6):968-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of Blm enhances basal cell carcinoma and rhabdomyosarcoma tumorigenesis in Ptch1+/- mice.
  • Basal cell carcinomas (BCCs) have relative genomic stability and relatively benign clinical behavior but whether these two are related causally is unknown.
  • The mutant Blm alleles also markedly enhanced the formation of rhabdomyosarcomas (RMSs), another cancer to which Ptch1(+/)(-) mice and PTCH1(+/)(-) (basal cell nevus syndrome) patients are susceptible.
  • Highly recurrent but different copy number changes were associated with the two tumor types and included losses of chromosomes 4 and 10 in all BCCs and gain of chromosome 10 in 80% of RMSs.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):71-83 [17943968.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10103-5 [17974949.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):743-54 [18813320.001]
  • [Cites] Dermatol Surg. 2009 Jan;35(1):131-4 [19076197.001]
  • [Cites] BMC Cancer. 2009;9:140 [19432957.001]
  • [Cites] Cancer Res. 2009 Jul 15;69(14):5768-75 [19584276.001]
  • [Cites] Nat Rev Cancer. 2009 Sep;9(9):644-54 [19657341.001]
  • [Cites] Leuk Res. 2010 Feb;34(2):210-20 [19709744.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Nat Genet. 2000 Dec;26(4):424-9 [11101838.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):741-6 [11257107.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2000;1:409-59 [11701636.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):6-7 [11753379.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):727-33 [12016144.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2013 [12242432.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2051-3 [12242442.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):5-6 [12509771.001]
  • [Cites] Hum Mol Genet. 2003 Nov 1;12(21):2837-44 [12952869.001]
  • [Cites] Curr Mol Med. 2003 Nov;3(7):589-96 [14601634.001]
  • [Cites] DNA Repair (Amst). 2003 Dec 9;2(12):1387-404 [14642567.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8578-81 [14695165.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4385-9 [15231643.001]
  • [Cites] Science. 1983 Aug 26;221(4613):851-3 [6879180.001]
  • [Cites] Hum Genet. 1985;71(3):187-91 [4065890.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(2):670-4 [2911598.001]
  • [Cites] Medicine (Baltimore). 1993 Nov;72(6):393-406 [8231788.001]
  • [Cites] J Biol Chem. 1994 Nov 25;269(47):29838-45 [7961977.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4566-73 [7527136.001]
  • [Cites] Cell. 1995 Nov 17;83(4):655-66 [7585968.001]
  • [Cites] Science. 1996 Apr 12;272(5259):258-62 [8602509.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jan;93(1):100-6 [9062585.001]
  • [Cites] Genes Dev. 1998 Nov 1;12(21):3382-93 [9808625.001]
  • [Cites] Oncogene. 1998 Nov 19;17(20):2565-71 [9840919.001]
  • [Cites] Genomics. 1998 Dec 15;54(3):443-52 [9878247.001]
  • [Cites] Genome Res. 2005 Feb;15(2):302-11 [15687294.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1567-75 [16273213.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2262-9 [16306523.001]
  • [Cites] J Med Genet. 2006 Feb;43(2):148-52 [15964893.001]
  • [Cites] Nucleic Acids Res. 2006;34(8):e58 [16670425.001]
  • [Cites] BMC Cancer. 2006;6:96 [16620391.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6606-14 [16818633.001]
  • [Cites] EMBO J. 2006 Jul 26;25(14):3422-31 [16858412.001]
  • [Cites] Mol Cell Biol. 2006 Sep;26(17):6713-26 [16914751.001]
  • [Cites] Cell. 2006 Nov 17;127(4):679-95 [17110329.001]
  • [Cites] J Cell Biol. 2007 Jul 2;178(1):9-14 [17591918.001]
  • [Cites] Mol Cancer Res. 2007 Jul;5(7):713-24 [17634426.001]
  • [Cites] Cell Mol Life Sci. 2007 Sep;64(17):2306-22 [17571213.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3558-60; discussion 3560-1 [18483234.001]
  • (PMID = 19995795.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA81888; United States / NCI NIH HHS / CA / CA84118
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.6.1.- / Bloom syndrome protein; EC 3.6.4.12 / RecQ Helicases
  • [Other-IDs] NLM/ PMC2878356
  •  go-up   go-down


47. Lash TL, Schmidt M, Jensen AØ, Engebjerg MC: Methods to apply probabilistic bias analysis to summary estimates of association. Pharmacoepidemiol Drug Saf; 2010 Jun;19(6):638-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In example one, the adjusted odds ratio associating glucocorticoid use with the rate of basal cell carcinoma was 1.15 (95%CI 1.07, 1.25).
  • In example two, the adjusted odds ratio associating concomitant use of clopidogrel and proton pump inhibitors with recurrent myocardial infarction was 1.21 (95%CI 0.90, 1.61).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20535760.001).
  • [ISSN] 1099-1557
  • [Journal-full-title] Pharmacoepidemiology and drug safety
  • [ISO-abbreviation] Pharmacoepidemiol Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Garvey C, Turner H: The use of a custom earmold to prevent recurrent external auditory canal stenosis. J Am Acad Audiol; 2008 Mar;19(3):233-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of a custom earmold to prevent recurrent external auditory canal stenosis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Constriction, Pathologic / prevention & control. Ear, External / pathology. Postoperative Complications. Stents
  • [MeSH-minor] Aged. Humans. Male. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672651.001).
  • [ISSN] 1050-0545
  • [Journal-full-title] Journal of the American Academy of Audiology
  • [ISO-abbreviation] J Am Acad Audiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


49. Bhandarkar ND, Sims HS, David O: ProEx C stain analysis in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol; 2010 Feb;119(2):99-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ProEx C stain analysis in recurrent respiratory papillomatosis.
  • OBJECTIVES: We evaluated the presence and pattern of ProEx C stain, a marker for the proliferative capacity of cells, in laryngeal tissues, including benign, malignant, and recurrent respiratory papilloma (RRP) specimens, and compared it to hematoxylin and eosin staining for the presence of dysplasia.
  • RESULTS: A total of 26 specimens (9 benign, 7 malignant, 10 RRP) representing 21 patients were stained.
  • The malignant specimens were either well or moderately differentiated squamous cell carcinoma, and they stained strongly and diffusely.
  • In benign and RRP specimens, the basal layer typically stained positive.
  • [MeSH-major] Antigens, Neoplasm / analysis. Cell Cycle Proteins / analysis. DNA Topoisomerases, Type II / analysis. DNA-Binding Proteins / analysis. Nuclear Proteins / analysis. Papilloma / chemistry. Respiratory Tract Neoplasms / chemistry
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy. Cell Proliferation. Diagnosis, Differential. Humans. Immunohistochemistry. Isoenzymes. Minichromosome Maintenance Complex Component 2. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20336920.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Isoenzymes; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


50. Raspagliesi F, Fontanelli R, Rossi G, Ditto A, Solima E, Hanozet F, Kusamura S: Photodynamic therapy using a methyl ester of 5-aminolevulinic acid in recurrent Paget's disease of the vulva: a pilot study. Gynecol Oncol; 2006 Nov;103(2):581-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy using a methyl ester of 5-aminolevulinic acid in recurrent Paget's disease of the vulva: a pilot study.
  • Photodynamic therapy (PDT) using 5-aminolevulinic acid (5 ALA) is an effective treatment for some conditions such as Bowen's disease, subsets of basal cell carcinomas and vulvar carcinoma.
  • This paper outlines a pilot study designed to test the feasibility of using MAL-PDT in the treatment of recurrent vulvar Paget's disease.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Paget Disease, Extramammary / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Vulvar Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793128.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / delta-aminolevulinic acid methyl ester; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


51. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R: Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery. J Am Acad Dermatol; 2005 Jun;52(6):997-1002
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery.
  • BACKGROUND: Bowen's disease (BD), also known as squamous intraepidermal carcinoma, is a malignant skin tumor with a potential to progress to invasive carcinoma.
  • In 50.7% of cases it was a recurrent tumor.
  • In 20% the tumor was initially misdiagnosed as basal cell carcinoma or squamous cell carcinoma.

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15928618.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


52. Simeonov R, Simeonova G: Nucleomorphometric analysis of feline basal cell carcinomas. Res Vet Sci; 2008 Jun;84(3):440-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleomorphometric analysis of feline basal cell carcinomas.
  • Twenty-four feline spontaneous basal cell carcinomas (BCCs) were analyzed by computerized nuclear morphometry.
  • The study included 15 non-recurrent and 9 recurrent tumours.
  • The analysis of data of the non-recurrent BCCs and the recurrent tumours revealed statistically significant differences between those groups (p<0.001) as well as between infiltrative and clear types of BCCs (p<0.05).
  • The results indicate that nuclear morphometry is able to predict recurrent tumour growth and helps to differentiate histological subtypes of BCCs in cats.
  • [MeSH-major] Carcinoma, Basal Cell / veterinary. Cat Diseases / pathology. Cell Nucleus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706734.001).
  • [ISSN] 0034-5288
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


53. Ulrich C, Johannsen A, Röwert-Huber J, Ulrich M, Sterry W, Stockfleth E: Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol; 2010 Jul-Aug;20(4):482-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Especially, invasive squamous cell carcinomas (SCC) in immuno-compromised patients are characterized by significantly increased morbidity and mortality and characteristically outnumber basal cell carcinoma in this population.
  • Despite recurrent AK in 55% of the previously cleared patients, the 24 month results showed no invasive SCC in this group.

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20507841.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Gels; 0 / Placebos; 144O8QL0L1 / Diclofenac; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


54. van der Zee J, Overgaard J: Hyperthermia classic commentary: 'Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology' by J. Overgaard, D. Gonzalez Gonzalez, M.C.C.H. Hulshof, G. Arcangeli, O. Dahl, O. Mella & S.M. Bentzen, International Journal of Hyperthermia 1996;12:3-20. Int J Hyperthermia; 2009 Aug;25(5):335-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermia classic commentary: 'Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology' by J. Overgaard, D. Gonzalez Gonzalez, M.C.C.H. Hulshof, G. Arcangeli, O. Dahl, O. Mella & S.M. Bentzen, International Journal of Hyperthermia 1996;12:3-20.
  • [MeSH-minor] Aged, 80 and over. Carcinoma, Basal Cell / surgery. Combined Modality Therapy. Female. Humans

  • Genetic Alliance. consumer health - Malignant hyperthermia.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Int J Hyperthermia. 2009 Aug;25(5):323-34 [19670088.001]
  • (PMID = 19670089.001).
  • [ISSN] 1464-5157
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Journal Article
  • [Publication-country] England
  •  go-up   go-down


55. Sung MT, Jiang Z, Montironi R, MacLennan GT, Mazzucchelli R, Cheng L: Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy. Hum Pathol; 2007 Feb;38(2):332-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alpha-methylacyl-CoA racemase (AMACR) has recently been shown to be a highly sensitive marker for the diagnosis of prostate cancer.
  • However, there is limited information concerning its utility as a marker for prostate carcinoma after hormonal therapy.
  • Our current investigation was conducted to evaluate the expression of AMACR in patients with prostate carcinoma after hormonal therapy and assess its diagnostic utility in combination with p63 and high molecular weight cytokeratin (34betaE12) staining.
  • All malignant acini were completely negative for both basal cell markers (34betaE12 and p63).
  • In all cases, basal cells were strongly stained by p63 in benign acini with a mean positive percentage of 96%.
  • Similarly, basal cells in benign acini displayed moderate staining intensities for 34betaE12 in 3 (7%) of 41 cases and strong immunostaining for this marker in the remaining 38 cases (93%); the mean percentage of positive cells was 92%.
  • alpha-methylacyl-CoA racemase expression may be substantially diminished or entirely lost in prostate carcinoma after hormonal therapy.
  • A triple cocktail stain using AMACR, 34betaE12, and p63 can be helpful in evaluating prostate specimens for the presence of residual or recurrent carcinoma after hormonal therapy for cancer.
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Humans. Immunohistochemistry / methods. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm, Residual. Reproducibility of Results. Transcription Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134736.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / CK-34 beta E12; 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


56. de Groot JW, Links TP, Rouwe CW, van der Wal JE, Hofstra RM, Plukker JT: [Prophylactic thyroidectomy in children who are carriers of a multiple endocrine neoplasia type 2 mutation: description of 20 cases and recommendations based on the literature]. Ned Tijdschr Geneeskd; 2006 Feb 11;150(6):311-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Profylactische thyreoïdectomie bij kinderen die drager zijn van een mutatie van multipele endocriene neoplasie type 2: beschrijving van 20 casussen en aanbevelingen op grond van de literatuur.
  • In 17 children with preoperatively abnormal basal or stimulated calcitonin levels, total thyroidectomy was combined with tracheo-oesophageal exploration (n = 6) or central compartment dissection (n = 11).
  • C-cell hyperplasia was found in 19 cases (95%) and medullary thyroid carcinoma in 14 (70%; aged 3-18 years).
  • Two children developed hypoparathyroidism postoperatively, no recurrent laryngeal-nerve palsy was observed.
  • The literature indicates that the progression of the malignant transformation to medullary thyroid carcinoma is connected to the type of RET-mutation.
  • After this age, however, the risk of lymph-node metastases increases and, for cases with increased basal or stimulated calcitonin levels, total thyroidectomy with central compartment dissection is indicated.
  • [MeSH-major] Carcinoma, Medullary / prevention & control. Multiple Endocrine Neoplasia Type 2a / prevention & control. Multiple Endocrine Neoplasia Type 2a / surgery. Proto-Oncogene Proteins c-ret / genetics. Thyroid Neoplasms / prevention & control. Thyroidectomy / methods

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • Genetic Alliance. consumer health - Multiple endocrine neoplasia, type 2.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16503023.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 9007-12-9 / Calcitonin; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human
  • [Number-of-references] 34
  •  go-up   go-down


57. Swanson EL, Amdur RJ, Mendenhall WM, Morris CG, Kirwan JM, Flowers F: Radiotherapy for basal cell carcinoma of the medial canthus region. Laryngoscope; 2009 Dec;119(12):2366-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for basal cell carcinoma of the medial canthus region.
  • OBJECTIVES/HYPOTHESIS: To report outcome for patients treated with radiotherapy (RT) for basal cell carcinoma of the medial canthus.
  • METHODS: Thirty-three patients treated with RT at the University of Florida between 1965 and 2005 for basal cell carcinoma of the medial canthus were retrospectively reviewed.
  • In patients treated with RT alone, the local control rate was 94% with de novo lesions and 67% if the lesion was recurrent after prior surgery.
  • Patients with recurrent tumors and gross disease at the time of RT have a suboptimal cure rate.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Eyelid Neoplasms / radiotherapy
  • [MeSH-minor] Dose-Response Relationship, Radiation. Follow-Up Studies. Humans. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19780029.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Ting PT, Kasper R, Arlette JP: Metastatic basal cell carcinoma: report of two cases and literature review. J Cutan Med Surg; 2005 Jan;9(1):10-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma: report of two cases and literature review.
  • BACKGROUND: Metastatic basal cell carcinoma (MBCC) is defined as primary cutaneous basal cell carcinoma (BCC) that spreads to distant sites as histologically similar metastatic deposits of BCC.
  • Patients with MBCC often begin with long-standing primary BCC lesions that are either large or recurrent after treatment.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / therapy. Facial Neoplasms / pathology. Facial Neoplasms / therapy
  • [MeSH-minor] Fatal Outcome. Female. Humans. Male. Middle Aged. Mohs Surgery. Neoplasm Metastasis. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16208438.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


59. Kudrina MI, Vinogradova NN, Kolen'ko NG, Zaev SN: [Skin tumours and primary multiple malignant neoplasms]. Klin Med (Mosk); 2009;87(2):60-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin tumours and primary multiple malignant neoplasms].
  • The structure of recurrent malignant neoplasms was analysed in a group of patients followed up on a permanent basis after the treatment for skin cancer.
  • Observation of 2801 patients with primary basal and squamous cell skin cancer during 32 years (1975-2006) revealed 740 recurrent malignant neoplasms largely affecting skin, gastrointestinal tract, lungs, mammary and prostate glands.
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Humans. Incidence. Male. Mass Screening / methods. Retrospective Studies. Russia / epidemiology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19348305.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


60. Desai RS, Donnelly HB: Repair of a glabellar and inferior forehead defect. Dermatol Surg; 2006 Jan;32(1):112-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This 44-year-old healthy white male was referred to our office for the treatment of a recurrent basal cell carcinoma clinically involving the left inferior forehead extending down to the left glabellar region of the face.
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Humans. Male. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2007 Jan;33(1):126-7 [17214696.001]
  • (PMID = 16393611.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Mc Loone NM, Tolland J, Walsh M, Dolan OM: Follow-up of basal cell carcinomas: an audit of current practice. J Eur Acad Dermatol Venereol; 2006 Jul;20(6):698-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follow-up of basal cell carcinomas: an audit of current practice.
  • BACKGROUND: Follow-up of patients after treatment of basal cell carcinoma (BCC) allows for monitoring of recurrence and detection of new tumours, but adds a significant burden to outpatient clinics.
  • Medical charts were reviewed to determine data recorded about lesions, the number of recurrent BCCs and new tumours detected, and the number of patients completing follow-up.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Guideline Adherence. Practice Guidelines as Topic. Skin Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Incidence. Male. Medical Audit. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / epidemiology. Practice Patterns, Physicians' / statistics & numerical data. Prognosis. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16836498.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


62. Livaoğlu M, Karacal N, Bektaş D, Bahadir O: Reconstruction of full-thickness nasal defect by free anterolateral thigh flap. Acta Otolaryngol; 2009 May;129(5):541-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four patients had a basal cell carcinoma, one an epidermoid carcinoma, and the other patient had recurrent malignant fibrous histiocytoma.
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Female. Histiocytoma, Benign Fibrous / surgery. Humans. Length of Stay. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Thigh / surgery

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607893.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


63. Allen C, Saigal K, Nottingham L, Arun P, Chen Z, Van Waes C: Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. Clin Cancer Res; 2008 Jul 1;14(13):4175-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Nuclear factor-kappaB (NF-kappaB)/REL transcription factors promote cancer cell survival and progression.
  • EXPERIMENTAL DESIGN: To examine these possibilities, matched biopsies from 24 h posttreatment were obtained from accessible tumors of patients who received low-dose bortezomib (0.6 mg/m(2)) before reirradiation in a phase I trial for recurrent head and neck squamous cell carcinoma (HNSCC).
  • Effects of bortezomib on apoptosis and proliferation by TUNEL and Ki67 staining were compared with nuclear staining for all five NF-kappaB subunits, phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2), and phosphorylated signal transducers and activators of transcription 3 (STAT3) in tumor biopsies, and by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTP) and DNA binding assay for the five NF-kappaB subunits in HNSCC cell lines.
  • In HNSCC cell lines, 10(-8) mol/L bortezomib inhibited cell density while inhibiting tumor necrosis factor-alpha-induced and partially inhibiting basal activation of NF-kappaB1/RELA, but not NF-kappaB2/RELB.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis. Boronic Acids / pharmacology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Gene Expression Regulation, Neoplastic. Head and Neck Neoplasms / metabolism. Head and Neck Neoplasms / pathology. NF-kappa B / metabolism. Pyrazines / pharmacology
  • [MeSH-minor] Bortezomib. Cell Nucleus / metabolism. DNA / chemistry. Humans. Models, Biological. Phosphorylation. Recurrence. Signal Transduction. Subcellular Fractions / metabolism

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18593997.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / NF-kappa B; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 9007-49-2 / DNA
  •  go-up   go-down


64. Lear W, Mittmann N, Barnes E, Breen D, Murray C: Cost comparisons of managing complex facial basal cell carcinoma: Canadian study. J Cutan Med Surg; 2008 Mar-Apr;12(2):82-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost comparisons of managing complex facial basal cell carcinoma: Canadian study.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common human malignancy and accounts for over 60,000 new cases of cancer in Canada annually.
  • All were located on the head and neck and were either recurrent disease or located in "at risk" sites such as the eye, ear, lip, or nose.
  • Although we did notice a trend toward greater costs in patients with recurrent disease, in males, younger patients, and tumors present for > 1 year, these did not reach significance within our sample size.
  • [MeSH-major] Carcinoma, Basal Cell / economics. Cost of Illness. Facial Neoplasms / economics. Mohs Surgery / economics. Skin Neoplasms / economics
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / economics. Ontario. Radiotherapy / economics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18346405.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Mosterd K, Arits AH, Thissen MR, Kelleners-Smeets NW: Histology-based treatment of basal cell carcinoma. Acta Derm Venereol; 2009;89(5):454-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histology-based treatment of basal cell carcinoma.
  • Basal cell carcinoma is the most common type of skin cancer and its incidence is still rising.
  • Selection criteria were histological subtype, primary or recurrent basal cell carcinoma and tumour localization.
  • Although surgery remains the preferred treatment for most basal cell carcinomas, patient and tumour characteristics should be taken into account when choosing the most suitable treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / therapy. Cryotherapy. Mohs Surgery. Photochemotherapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Evidence-Based Medicine. Humans. Neoplasm Invasiveness. Patient Selection. Randomized Controlled Trials as Topic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Derm Venereol. 2009;89(5):450-2 [19734965.001]
  • [ErratumIn] Acta Derm Venereol. 2009 Nov;89(6):667
  • (PMID = 19734968.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 36
  •  go-up   go-down


66. Leibl S, Moinfar F: Mammary NOS-type sarcoma with CD10 expression: a rare entity with features of myoepithelial differentiation. Am J Surg Pathol; 2006 Apr;30(4):450-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our immunohistochemical antibody panel included pan-cytokeratin (CK), basal cell type CKs (34betaE12, CK5/6, CK14, CK17) and vimentin antibodies, antibodies to established (SMA, CD10, p63, S-100, maspin, calponin, GFAP, SM-myosin), and novel (CD29, 14-3-3sigma) myoepithelial markers, as well as antibodies to CD34, desmin, h-caldesmon, steroid receptors (estrogen, progesterone, androgen), and EGFR (Her-1).
  • Phyllodes tumors with stromal overgrowth or recurrent phyllodes tumors lacking epithelial structures as well as periductal stromal sarcomas can be ruled out by their frequent expression of CD34 and negativity for myoepithelial markers.
  • The most important differential diagnosis is sarcomatoid metaplastic carcinoma because its treatment includes axillary lymphadenectomy.
  • Since some NOS-type sarcomas with CD10 expression and most metaplastic carcinomas show positivity for CD29, SMA, and p63, differential diagnosis can be extremely difficult and requires extensive immunohistochemical evaluation for CKs and additional myoepithelial markers such as S-100, 14-3-3sigma, and maspin.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinosarcoma / diagnosis. Cell Transformation, Neoplastic. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged


67. Tawfik HA, Assem M, Elkafrawy MH, Talib NM: Scar sarcoidosis developing 16 years after complete excision of an eyelid Basal carcinoma. Orbit; 2008;27(6):438-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scar sarcoidosis developing 16 years after complete excision of an eyelid Basal carcinoma.
  • A 56-year-old patient developed sarcoidosis on top of an old eyelid scar from previous removal of an eyelid basal cell carcinoma 16 years prior to presentation.
  • Sarcoidosis should be considered in the differential diagnosis of recurrent eyelid skin cancers especially if the external appearance or the duration after the initial surgery does not fit the criteria for recurrence.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Postoperative Complications. Sarcoidosis / etiology
  • [MeSH-minor] Cicatrix / diagnosis. Cicatrix / etiology. Diagnosis, Differential. Female. Humans. Middle Aged. Ophthalmologic Surgical Procedures


68. Huerva V, Sanchez MC, Egido RM, Matías-Guiu X: Pleomorphic adenoma with extensive myoepithelial component (myoepithelioma) of the lower eyelid. Ophthal Plast Reconstr Surg; 2008 May-Jun;24(3):223-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On presentation to us, the lesion showed a clinical appearance that was very similar to a nodular basal cell carcinoma.
  • A diagnosis of pleomorphic adenoma with extensive myoepithelial component (myoepithelioma) was made.
  • The authors conclude that myoepithelioma should be considered in the differential diagnosis of nodular recurrent masses in the eyelids of adults.
  • Definitive diagnosis is possible only after surgical biopsy.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Eyelid Neoplasms / pathology. Myoepithelioma / pathology. Neoplasm Recurrence, Local. Neoplasms, Multiple Primary
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Middle Aged. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520841.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


69. Griffiths RW, Suvarna SK, Stone J: Do basal cell carcinomas recur after complete conventional surgical excision? Br J Plast Surg; 2005 Sep;58(6):795-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do basal cell carcinomas recur after complete conventional surgical excision?
  • For 1378 patients treated in the 11 years 1988-1998 by conventional excision of 1635 basal cell carcinomas, 1516 first index lesions were histologically completely excised.
  • Measured clearance margins around the initial lesions at or near sites of presumptive recurrent lesions were noted and the lesions recorded photographically.
  • These figures indicate there is a low order of probability for the incidence of recurrent basal cell carcinoma during minimum 5 years follow period after conventional surgical excision and conventional histological assessment of tumour resection margins.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Plast Reconstr Aesthet Surg. 2007;60(4):451-3 [17349608.001]
  • [CommentIn] J Plast Reconstr Aesthet Surg. 2006;59(11):1247 [17046636.001]
  • (PMID = 16086990.001).
  • [ISSN] 0007-1226
  • [Journal-full-title] British journal of plastic surgery
  • [ISO-abbreviation] Br J Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


70. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R: Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol; 2005 Sep;53(3):452-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up.
  • BACKGROUND: Long-term follow-up is essential to evaluate the role of Mohs micrographic surgery (MMS) in the treatment for cutaneous basal cell carcinoma (BCC).
  • Fifty-six percent of the tumors were primary and 44% were previously recurrent.
  • Recurrence at 5 years was diagnosed in 1.4% of primary and in 4% of recurrent tumors.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Head and Neck Neoplasms / surgery. Mohs Surgery. Skin Neoplasms / surgery


71. Fukuda I, Hizuka N, Ishikawa Y, Yasumoto K, Murakami Y, Sata A, Morita J, Kurimoto M, Okubo Y, Takano K: Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm IGF Res; 2006 Aug;16(4):211-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia.
  • In some patients with non-islet-cell tumor hypoglycemia (NICTH), a high molecular weight form of IGF-II (big IGF-II) derived from tumors is present in the circulation and might be associated with recurrent hypoglycemia.
  • Hepatocellular carcinoma and gastric carcinoma were the most common causes of NICTH.
  • Basal immunoreactive insulin (IRI) levels were less than 3 microU/dl in 79% of the patients.
  • These data suggested that hypoinsulinemic hypoglycemia associated with the presence of a large tumor supports the diagnosis of IGF-II producing NICTH.
  • [MeSH-minor] Adolescent. Adrenal Gland Neoplasms / secretion. Adult. Aged. Aged, 80 and over. Blood Glucose / analysis. Breast Neoplasms / secretion. Carcinoma, Hepatocellular / secretion. Carcinoma, Renal Cell / secretion. Child. Female. Fibrosarcoma / secretion. Gastrointestinal Stromal Tumors / secretion. Humans. Insulin-Like Growth Factor I / analysis. Insulin-Like Growth Factor II. Leiomyosarcoma / secretion. Liver Neoplasms / secretion. Male. Middle Aged. Pancreatic Neoplasms / secretion. Pheochromocytoma / secretion. Prostatic Neoplasms / secretion. Retrospective Studies. Stomach Neoplasms / secretion

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • Genetic Alliance. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860583.001).
  • [ISSN] 1096-6374
  • [Journal-full-title] Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • [ISO-abbreviation] Growth Horm. IGF Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / IGF2 protein, human; 0 / Proteins; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


72. Ek EW, Giorlando F, Su SY, Dieu T: Clinical diagnosis of skin tumours: how good are we? ANZ J Surg; 2005 Jun;75(6):415-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical diagnosis of skin tumours: how good are we?
  • BACKGROUND: Few studies have addressed the accuracy of clinical diagnosis of skin malignancies.
  • The present prospective study aims to determine the accuracy with which these lesions are diagnosed and attempts to identify the factors influencing the accuracy of clinical diagnosis.
  • Of these 47% were basal cell carcinomas (BCC), 20% were squamous cell carcinomas (SCC), 0.9% were malignant melanomas (MM), and 32.1% were benign or premalignant.
  • Tumours, benign and malignant, were found to be more common in men.
  • The sensitivity for clinical diagnosis of malignancy was 97.5% while the positive predictive value (PPV) for clinical diagnosis of malignancy was 70.3%.
  • 23 MM were excised with a sensitivity of clinical diagnosis of 47.8% and PPV of 30.6%.
  • Sensitivity and PPV were also assessed according to clinical experience of the surgeon, site of the lesion and whether surgery was performed for a primary or a recurrent lesion.
  • [MeSH-major] Skin Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Female. Humans. Male. Melanoma / diagnosis. Middle Aged. Precancerous Conditions / diagnosis. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity


73. Siegmund SV, Singer MV: [Effects of alcohol on the upper gastrointestinal tract and the pancreas--an up-to-date overview]. Z Gastroenterol; 2005 Aug;43(8):723-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic consumption of alcohol causes a significant increase in the risk for squamous carcinoma of the oesophagus.
  • In the exocrine pancreas, alcohol induces secretory alterations that are mainly affected by the manner and duration of alcohol exposure, the additional administration of food, the type of beverage or the basal secretory state of the gland.
  • Chronic alcohol abuse may cause chronic alcoholic pancreatitis after recurrent subclinical inflammatory episodes.
  • [MeSH-minor] Acute Disease. Carcinoma, Squamous Cell / etiology. Esophageal Neoplasms / etiology. Gastric Acid / secretion. Gastritis / etiology. Gastrointestinal Motility / drug effects. Genetic Predisposition to Disease. Humans. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16088770.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  • [Number-of-references] 192
  •  go-up   go-down


74. Shome D, Bell D, Esmaeli B: Eyelid carcinoma in patients with systemic lymphoma. J Ophthalmic Vis Res; 2010 Jan;5(1):38-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid carcinoma in patients with systemic lymphoma.
  • PURPOSE: To describe a series of patients with Non-Hodgkin's lymphoma (NHL) and concomitant eyelid carcinoma.
  • METHODS: In this non-comparative interventional case series, we retrospectively reviewed the medical records of 5 patients with NHL who developed eyelid carcinoma.
  • Systemic lymphoma had been diagnosed 1 to 72 months prior to development of the eyelid carcinoma.
  • The lesions were basal cell carcinoma in three, and squamous cell carcinoma in two cases.
  • Four patients underwent surgical excision of the carcinoma and one patient was awaiting surgical treatment after completing systemic chemotherapy.
  • Two patients had perineural invasion; one received adjuvant radiotherapy postoperatively but the other did not due to receiving systemic chemotherapy for recurrent NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1975 Apr 21;232(3):267-9 [47401.001]
  • [Cites] J Natl Cancer Inst. 1978 Aug;61(2):337-40 [277720.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] BMJ. 1995 Jun 10;310(6993):1491-5 [7787593.001]
  • [Cites] Curr Opin Hematol. 2000 Jul;7(4):223-34 [10882178.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2008 Nov-Dec;24(6):444-9 [19033839.001]
  • [Cites] Am J Ophthalmol. 1986 Apr 15;101(4):480-2 [3515953.001]
  • [Cites] Arch Ophthalmol. 1980 Oct;98(10):1771-2 [7000053.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] Br J Cancer. 1996 Dec;74(11):1847-50 [8956805.001]
  • [Cites] Acta Haematol. 1997;98(1):44-6 [9210914.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):641-5 [10048959.001]
  • [Cites] Dermatology. 2001;202(4):359-61 [11455161.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] Curr Treat Options Oncol. 2004 Jun;5(3):215-23 [15115650.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):507-13 [15160912.001]
  • [Cites] Histopathology. 2004 Aug;45(2):162-70 [15279635.001]
  • [Cites] Arch Dermatol. 2004 Aug;140(8):985-8 [15313816.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):49-54 [15621780.001]
  • [Cites] Dermatol Surg. 2005 Jan;31(1):38-42; discussion 42 [15720094.001]
  • [Cites] Leuk Lymphoma. 2005 Jul;46(7):1051-5 [16019557.001]
  • [Cites] Skinmed. 2005 Sep-Oct;4(5):300-4 [16282752.001]
  • [Cites] Australas J Dermatol. 2006 Nov;47(4):231-6 [17034463.001]
  • (PMID = 22737325.001).
  • [ISSN] 2008-2010
  • [Journal-full-title] Journal of ophthalmic & vision research
  • [ISO-abbreviation] J Ophthalmic Vis Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC3380669
  • [Keywords] NOTNLM ; Eyelid Cancer / Immunosuppression / Squamous Cell Carcinoma / Systemic Lymphoma
  •  go-up   go-down


75. Chen WL, Yang ZH, Huang ZQ, Chai Q, Zhang DM: Facial contour reconstruction after benign tumor ablation using reverse facial-submental artery deepithelialized submental island flaps. J Craniofac Surg; 2010 Jan;21(1):83-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrent pleomorphic adenoma in the cheek and inferior temple was present in 3 patients, and recurrent basal cell adenoma was present in 1.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Reconstructive Surgical Procedures / methods. Surgical Flaps / blood supply
  • [MeSH-minor] Adult. Cheek. Female. Forehead. Humans. Male. Neoplasm Recurrence, Local / surgery. Postoperative Complications. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061969.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Nemet AY, Deckel Y, Martin PA, Kourt G, Chilov M, Sharma V, Benger R: Management of periocular basal and squamous cell carcinoma: a series of 485 cases. Am J Ophthalmol; 2006 Aug;142(2):293-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of periocular basal and squamous cell carcinoma: a series of 485 cases.
  • PURPOSE: To analyze the outcome of management of patients with basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) in a tertiary referral eye center in Sydney, Australia.
  • Twenty-seven patients (5.6%) had a recurrent tumor.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Eyelid Neoplasms / surgery. Neoplasm Recurrence, Local. Skin Neoplasms / surgery


77. Reddy KK, Hanke CW, Tierney EP: Rapid wound re-epithelialization and basal cell carcinoma clearance after Mohs micrographic surgery with postoperative photodynamic therapy. J Drugs Dermatol; 2010 Feb;9(2):143-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid wound re-epithelialization and basal cell carcinoma clearance after Mohs micrographic surgery with postoperative photodynamic therapy.
  • BACKGROUND: Methyl aminolevulinic acid photodynamic therapy (MAL-PDT) has antitumor activity and may promote wound healing Superficial and nodular basal cell carcinomas (BCCs) have been successfully treated with MAL-PDT in prior reports.
  • CASE REPORT: A patient presented for Mohs micrographic surgery (MMS) after recent biopsy revealed recurrent BCC.
  • Review of the literature relevant to use of MAL-PDT in treatment of basal cell carcinoma and literature describing effects of PDT on wound healing was performed.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Mohs Surgery. Photochemotherapy. Skin Neoplasms / therapy. Wound Healing

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20214177.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Paavilainen V, Aaltonen M, Tuominen J, Saari KM: Histological characteristics of basal cell carcinoma of the eyelid. Ophthalmic Res; 2007;39(1):45-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological characteristics of basal cell carcinoma of the eyelid.
  • PURPOSE: To evaluate the histological subtypes of basal cell carcinoma (BCC) of the eyelid and to determine their effect on the size, depth of invasion and need of retreatment of a nonselected patient material seen in south-western Finland.
  • CONCLUSIONS: The nodular subtype of BCC should be regarded as a potentially invasive and recurrent tumor.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164577.001).
  • [ISSN] 0030-3747
  • [Journal-full-title] Ophthalmic research
  • [ISO-abbreviation] Ophthalmic Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


79. Rodriguez-Vigil T, Vázquez-López F, Perez-Oliva N: Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. J Am Acad Dermatol; 2007 Jan;56(1):91-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation.
  • BACKGROUND: The incidence of basal cell carcinoma (BCC) is increasing.
  • Exclusion criteria for study entry included: recurrent BCC, fibrosing BCC, ill-defined BCC, and BCC larger than 10 mm in diameter (high-risk facial sites) or larger than 15 mm in diameter (medium-risk sites); BCC smaller than 4 mm; and nonbiopsy-proven BCC.
  • The primary outcome was recurrence of carcinoma, which was clinically evaluated by at least two observers in consensus.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Curettage. Electrocoagulation. Facial Neoplasms / epidemiology. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / epidemiology


80. Hagikura M, Murakumo Y, Hasegawa M, Jijiwa M, Hagiwara S, Mii S, Hagikura S, Matsukawa Y, Yoshino Y, Hattori R, Wakai K, Nakamura S, Gotoh M, Takahashi M: Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression. Pathol Int; 2010 Nov;60(11):735-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bladder cancer is one of the most common malignant diseases.
  • Since a high-rate of recurrence is a serious problem for early stage urothelial carcinomas, new strategies for the management of recurrent urothelial carcinomas have been explored.
  • CD109 is a glycosylphosphatidylinositol-anchored glycoprotein and is expressed in various cancer tissues, mainly squamous cell carcinomas.
  • Of 156 urothelial carcinoma tissues, 69.9% were positive for CD109, whereas CD109 was not expressed in seven normal bladder epithelia.
  • Interestingly, CD109 was found to be highly expressed in the basal layer of non-invasive urothelial carcinomas, and the expression pattern was similar to that of CD44, a marker of cancer stem cells.
  • [MeSH-major] Antigens, CD / metabolism. Carcinoma / pathology. Neoplasm Proteins / metabolism. Urinary Bladder Neoplasms / pathology. Urothelium / pathology
  • [MeSH-minor] Female. GPI-Linked Proteins / metabolism. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Neoplasm Staging. Phosphorylation. Smad2 Protein / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Pathology International © 2010 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd.
  • (PMID = 20946523.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD109 protein, human; 0 / GPI-Linked Proteins; 0 / Neoplasm Proteins; 0 / Smad2 Protein
  •  go-up   go-down


81. Naumann IC, Cordes SR: Giant basal cell carcinoma of the forehead with extensive intracranial involvement. Ann Otol Rhinol Laryngol; 2007 Sep;116(9):663-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinoma of the forehead with extensive intracranial involvement.
  • Basal cell carcinoma (BCC) is the most common malignant skin lesion and is frequently curatively treated with local excision.
  • We describe a case of a recurrent BCC that aggressively grew from the forehead skin through the skull and into the frontal lobe.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Forehead. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neurosurgical Procedures / methods. Reconstructive Surgical Procedures / methods. Severity of Illness Index. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17926588.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Terziqi H, Tarpila E: Reconstruction of large defect of lower lip and commissure using Karapandzic flap: case report. Niger J Med; 2009 Apr-Jun;18(2):222-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present an 18-years-old boy with XP and recurrent basal and squamous cell carcinoma of lower lip.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Lip Neoplasms / surgery. Reconstructive Surgical Procedures. Surgical Flaps. Xeroderma Pigmentosum / pathology
  • [MeSH-minor] Adolescent. Humans. Male. Neoplasm Recurrence, Local / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19630336.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


83. Nasir S, Kayikcioglu A, Aydin MA, Tunçbilek G: Coverage of the cranium with latissimus dorsi in the recurrent basal cell carcinoma of Gorlin syndrome: for protection against clinical invasion. J Craniofac Surg; 2006 May;17(3):599-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coverage of the cranium with latissimus dorsi in the recurrent basal cell carcinoma of Gorlin syndrome: for protection against clinical invasion.
  • Gorlin's syndrome is a genetic disorder of autosomal dominant inheritance with characterized primarily by five major findings: multiple basal cell carsinoma (BCC), jaw cysts, pits on the palms and soles, ectopic calcification of the falx cerebri and skeletal anomalies.
  • The risk of recurrent BCC with Gorlin's syndrome is higher than non-syndromic BCC.
  • The authors present a 25-year-old man affected by recurrent basal cell carcinoma on the scalp.
  • Muscle tissue transformed in scalp reconstruction imitates the fascia layer in forming an additional layer against the invasion of skin tumors such as recurrent BCC into the cranium.
  • Free flap reconstruction for recurrent scalp BCC can be best therapy model at Gorlin's syndrome.
  • [MeSH-major] Basal Cell Nevus Syndrome / surgery. Carcinoma, Basal Cell / surgery. Muscle, Skeletal / transplantation. Scalp / surgery. Skin Neoplasms / surgery. Skull / surgery
  • [MeSH-minor] Adult. Clinical Protocols. Fascia / transplantation. Follow-Up Studies. Humans. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / surgery. Skin Transplantation / methods

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770207.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Cuellar F, Vilalta A, Puig S, Palou J, Zaballos P, Malvehy J: Dermoscopy of early recurrent basal cell carcinoma. Arch Dermatol; 2008 Sep;144(9):1254
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopy of early recurrent basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Dermoscopy. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794487.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Griffin JR, Cohen PR, Tschen JA, Mullans EA, Schulze KE, Martinelli PT, Nelson BR: Basal cell carcinoma in childhood: case report and literature review. J Am Acad Dermatol; 2007 Nov;57(5 Suppl):S97-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma in childhood: case report and literature review.
  • Childhood onset basal cell carcinoma is uncommon.
  • In addition to occurring in children with albinism, Bazex syndrome, basal cell carcinoma nevus syndrome, nevus sebaceus, radiotherapy-treated cancers, solid organ transplants, and xeroderma pigmentosum, childhood onset basal cell carcinoma has also occurred, albeit less commonly, de novo.
  • We describe a boy with idiopathic childhood onset basal cell carcinoma.
  • Previously published children with de novo basal cell carcinoma were collected from computerized medical literature search (PubMed) and citations from earlier reports.
  • To our knowledge, childhood onset idiopathic basal cell carcinoma has been observed in a total of 107 children, including our patient.
  • Basal cell carcinoma in children may be associated with prior sun exposure.
  • However, 15 of 85 children, nearly 20%, developed recurrent tumors during a follow-up period ranging from 4 months to 20 years.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Nose Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938034.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


86. Mátrai Z, Plotár V, Liszkay G, Fejos Z, Vámosi A, Dubóczky Z, Rényi Vámos F, Vámosi Nagy I, Köves I, Bartal A, Schmidt E, Tóth L: [Recurrent acral lentigous melanoma successfully treated with Mohs' micrographic surgery. Case report and review of the literature]. Orv Hetil; 2009 Jun 7;150(23):1071-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent acral lentigous melanoma successfully treated with Mohs' micrographic surgery. Case report and review of the literature].
  • Mohs' micrographic surgery is the method of choice for removal of large, recurrent or incompletely excised skin cancers or for tumors located in functional and aesthetic relevant anatomic regions.
  • The authors present a case of a 75-year-old man with a second time recurrent plantar invasive malignant melanoma successfully treated with Mohs' micrographic surgery technique and an immediate reconstruction using split-thickness skin graft.
  • [MeSH-major] Melanoma / pathology. Melanoma / surgery. Mohs Surgery / methods. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Frozen Sections. Humans. Male. Skin Transplantation. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19470423.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 46
  •  go-up   go-down


87. Leyngold M, Leyngold I, Letourneau PR, Zamboni WA, Shah H: Basal cell carcinoma and rhinophyma. Ann Plast Surg; 2008 Oct;61(4):410-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma and rhinophyma.
  • Basal cell carcinoma (BCC) is a rare finding in patients with rhinophyma.
  • The patient suffered from chronic drainage and recurrent infections that failed conservative treatment with oral and topical antibiotics.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Nose Deformities, Acquired / surgery. Nose Neoplasms / surgery. Precancerous Conditions / surgery. Rhinophyma / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic. Humans. Male. Nose / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812712.001).
  • [ISSN] 1536-3708
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Sebastián Villalón-López J, Arturo Valle-Mejía C, Patiño-Lara A, Moreno-Pérez Bertha A, Alejo Muñoz-López J, Alcantar-Andrade A: Supraestructure maxillectomy and orbital exenteration for treatment of basal cell carcinoma of inferior eyelid: case report and review. J Cancer Res Ther; 2005 Jul-Sep;1(3):132-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supraestructure maxillectomy and orbital exenteration for treatment of basal cell carcinoma of inferior eyelid: case report and review.
  • Basal cell carcinoma (BCC) is the most frequent type of skin cancer in humans, with cumulative exposure to ultraviolet radiation (UVR) as important risk factor for development of the illness as such as severe solar burns during childhood or adolescence.
  • Orbital exenteration is also used for treatment of malignancies of ocular tissues, mainly squamous cell carcinoma, sebaceous cell carcinoma and BCC.
  • The case of a 77 year-old patient is presented with BCC of inferior eyelid of 14 years duration, formerly managed with radiotherapy and, due to recurrent illness and invasion to the maxillary antrum; he needed supraestructure maxillectomy with left orbital exenteration.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Maxilla / surgery. Orbit Evisceration / methods
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / drug therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998643.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 15
  •  go-up   go-down


89. Su SY, Giorlando F, Ek EW, Dieu T: Incomplete excision of basal cell carcinoma: a prospective trial. Plast Reconstr Surg; 2007 Oct;120(5):1240-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incomplete excision of basal cell carcinoma: a prospective trial.
  • Reported rates of incomplete excision of basal cell carcinoma vary widely (5 to 25 percent) among centers worldwide.
  • METHODS: From January of 2001 to December of 2002, 1214 basal cell carcinomas were excised at Peter MacCallum Cancer Centre.
  • Risk factors for incomplete excision are the head site; morpheic, superficial, and infiltrative subtypes; lesions larger than 20 mm in diameter; the presence of multiple lesions; repair by skin graft; and recurrent and previously incompletely excised basal cell carcinomas.
  • CONCLUSIONS: This is the largest prospective study of incomplete excision of basal cell carcinomas.
  • Preoperative "red-flagging" of basal cell carcinomas most at risk of incomplete excision may lead to a better result.
  • [MeSH-major] Carcinoma, Basal Cell / ultrasonography. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / surgery. Prospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17898596.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Lonsdorf AS, Becker MR, Stockfleth E, Schäkel K, Ulrich C: [Primary and secondary prevention of skin cancer in organ transplant recipients]. Hautarzt; 2010 Mar;61(3):195-206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whereas the risk for malignant melanoma is only moderately increased, non-melanoma skin cancers (NMSC) seem to thrive on chronic immunosuppression and account for up to 95% of post-transplant cutaneous malignancies.
  • Compared to the general population cutaneous squamous cell carcinoma (SCC) and actinic keratoses (AK) characteristically show even higher incidences than basal cell carcinoma (BCC) and act as an indicator for the development of multiple primary cutaneous neoplasias and locally recurrent cancers (field cancerization).
  • Early diagnosis and therapy of pre-malignant cutaneous lesions is crucial for the secondary prophylaxis of further invasive and highly aggressive skin cancers.

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):28-33 [15842610.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Curr Opin Investig Drugs. 2002 Feb;3(2):295-304 [12020063.001]
  • [Cites] Lancet. 1992 Jul 4;340(8810):48-9 [1351617.001]
  • [Cites] Arch Dermatol. 2005 Aug;141(8):978-82 [16103326.001]
  • [Cites] Br J Dermatol. 2006 Mar;154(3):395-400 [16445766.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):628-33 [15061847.001]
  • [Cites] J Invest Dermatol. 2000 Jul;115(1):37-41 [10886505.001]
  • [Cites] J Am Acad Dermatol. 2004 Feb;50(2):189-96 [14726871.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):976-90 [1607418.001]
  • [Cites] Arch Dermatol. 2005 Aug;141(8):985-93 [16103328.001]
  • [Cites] Br J Dermatol. 2007 May;156 Suppl 3:40-2 [17488405.001]
  • [Cites] J Am Acad Dermatol. 2005 Nov;53(5):783-90 [16243126.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):656-61 [15061851.001]
  • [Cites] J Invest Dermatol. 2007 Jul;127(7):1647-56 [17380113.001]
  • [Cites] Science. 2005 Sep 16;309(5742):1871-4 [16166520.001]
  • [Cites] Br J Dermatol. 1999 Apr;140(4):656-60 [10233316.001]
  • [Cites] J Am Acad Dermatol. 1998 Aug;39(2 Pt 3):S82-5 [9703130.001]
  • [Cites] Am J Transplant. 2008 Nov;8(11):2192-8 [18782290.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):407-12 [12963902.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):569-74 [16374480.001]
  • [Cites] Br J Dermatol. 2009 Nov;161 Suppl 3:78-84 [19775361.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1758-64 [10223570.001]
  • [Cites] Am J Transplant. 2004 Jun;4(6):905-13 [15147424.001]
  • [Cites] Br J Dermatol. 2007 Feb;156(2):320-8 [17223873.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):561-4 [11442593.001]
  • [Cites] Methods. 2002 Sep;28(1):55-62 [12231188.001]
  • [Cites] Am J Transplant. 2005 Sep;5(9):2079-84 [16095486.001]
  • [Cites] Ann N Y Acad Sci. 2001 Dec;952:109-15 [11795429.001]
  • [Cites] Arch Dermatol. 2004 Aug;140(8):1015-6 [15313829.001]
  • [Cites] Australas J Dermatol. 2002 Nov;43(4):269-73 [12423433.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] Transplantation. 1993 Apr;55(4):742-7 [8475546.001]
  • [Cites] Br J Dermatol. 2002 Oct;147(4):816-8 [12366444.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:25-31 [18067628.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):622-7 [15061846.001]
  • [Cites] Br J Dermatol. 2004 Oct;151(4):837-45 [15491425.001]
  • [Cites] Acta Derm Venereol. 2006;86(1):25-8 [16585985.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):916-25 [17034519.001]
  • [Cites] Neoplasia. 2001 Jan-Feb;3(1):53-61 [11326316.001]
  • [Cites] Lancet. 1998 Feb 28;351(9103):623-8 [9500317.001]
  • [Cites] Arch Dermatol. 2001 Apr;137(4):459-63 [11295926.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):196-200 [15270891.001]
  • (PMID = 20177652.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


91. Cohen PR, Schulze KE, Nelson BR: Basal cell carcinoma with mixed histology: a possible pathogenesis for recurrent skin cancer. Dermatol Surg; 2006 Apr;32(4):542-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with mixed histology: a possible pathogenesis for recurrent skin cancer.
  • BACKGROUND: Basal cell carcinoma with mixed histology (BCC-MH) demonstrates more than one pathologic pattern of tumor.
  • Appropriate therapy for the nonaggressive tumor subtype diagnosed from a superficial biopsy may not be adequate to treat the unsuspected aggressive tumor subtype, resulting in recurrent skin cancer.
  • CONCLUSION: More than 40% of basal cell carcinomas referred for removal of the residual tumor were BCC-MH.
  • Subsequently, the cancer may recur if the initial treatment for the diagnosed nonaggressive tumor subtype is inadequate for the undiscovered aggressive carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Facial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681663.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 66
  •  go-up   go-down


92. Wadhera A, Fazio M, Bricca G, Stanton O: Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data? Dermatol Online J; 2006;12(5):7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data?
  • A 55-year-old man presented to Skin Cancer Surgery Center of Sacramento in 1995 for Mohs micrographic surgery of a 1.5-cm nodular basal cell carcinoma located on the right superior antihelix and scaphoid fossa.
  • A recurrent basal cell carcinoma developed at the same site 5 years later and was treated also by Mohs micrographic surgery.
  • One year later (approximately 6 years after the diagnosis of the initial basal cell carcinoma), a right parotid mass was noted on routine physical exam.
  • CT scan and fine needle aspiration of the mass revealed metastatic basal cell carcinoma.
  • He has done well for the past 2 years since the diagnosis of his metastatic lesion.
  • Basal cell carcinoma is the most common malignancy in the world.
  • We report a case of basal cell carcinoma metastatic to the parotid gland and critically review the incidence data reported in the literature.
  • We recommended the collection of more current and accurate incidence data for basal cell carcinoma and metastatic basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Ear Neoplasms / pathology. Parotid Neoplasms / secondary
  • [MeSH-minor] Humans. Incidence. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16962022.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


93. Freier K, Flechtenmacher C, Devens F, Hartschuh W, Hofele C, Lichter P, Joos S: Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma. Oncol Rep; 2006 May;15(5):1141-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma.
  • Formation of basal cell carcinoma (BCC) has been linked to deregulation in the sonic hedgehogh (Shh) signalling pathway.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Gene Dosage. Genes, myc / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596176.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


94. Wagamon K, Li LJ: Recurrent invasive basal cell carcinoma after radiation and imiquimod: a case report. Dermatol Surg; 2007 Jan;33(1):117-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent invasive basal cell carcinoma after radiation and imiquimod: a case report.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / therapy. Nasal Cavity. Neoplasm Recurrence, Local / therapy. Nose Neoplasms / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214692.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


95. Moskalik K, Kozlow A, Demin E, Boiko E: Powerful neodymium laser radiation for the treatment of facial carcinoma: 5 year follow-up data. Eur J Dermatol; 2010 Nov-Dec;20(6):738-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Powerful neodymium laser radiation for the treatment of facial carcinoma: 5 year follow-up data.
  • A retrospective non-comparative follow-up study was performed to evaluate the curative efficacy of powerful neodymium laser radiation (λ = 1,060 nm) for the treatment of 2,837 patients with 3,001 histologically confirmed facial skin carcinoma lesions of stages T1-2N0M0: 2,743 primary basal cell carcinomas (BCC), 172 recurrent limited basal cell carcinomas (RLBCC), and 86 primary squamous cells carcinomas (SCC).
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Facial Neoplasms / radiotherapy. Laser Therapy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neodymium. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21056940.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 2I87U3734A / Neodymium
  •  go-up   go-down


96. Taylor SF, Cook AE, Leatherbarrow B: Review of patients with basal cell nevus syndrome. Ophthal Plast Reconstr Surg; 2006 Jul-Aug;22(4):259-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of patients with basal cell nevus syndrome.
  • PURPOSE: To review patients with basal cell nevus syndrome (BCNS), documenting presentation, referrals, treatment patterns, and associated morbidity.
  • Demographic data, age at presentation, age at diagnosis, spectrum of ophthalmic and periocular disease, treatment modalities used, and periocular deformities developed were reviewed.
  • Presenting clinical features included odontogenic keratocyst in 17 patients and basal cell carcinoma in 13 patients; less common presentations were with congenital malformations (n = 2), with ophthalmic associations (n = 3), and at genetic counseling (n = 4).
  • Seventeen of the 39 patients confirmed a parental diagnosis of BCNS.
  • Basal cell carcinoma developed in 18 of the 28 patients before the age of 30, confirming the reported early age of onset.
  • Periocular basal cell carcinoma was reported in 24 of 39 patients (61%), with recurrent disease reported in 17 of these 24 (71%), despite a variety of treatment modalities used.
  • CONCLUSIONS: Patients with BCNS frequently have ophthalmic manifestations, particularly periocular basal cell carcinoma.
  • Early diagnosis of BCNS may allow for skin protection and surveillance at an earlier age.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Basal Cell / pathology. Child. Child, Preschool. Cross-Sectional Studies. Eye Diseases / diagnosis. Eyelid Neoplasms / pathology. Female. Genetic Counseling. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Nevus.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855496.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Farhadi M, Kamrava SK, Behzadi AH, Rafiezadeh P, Asghari A, Rezvan F, Maleki S: The efficacy of photodynamic therapy in treatment of recurrent squamous cell and basal cell carcinoma. J Drugs Dermatol; 2010 Feb;9(2):122-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of photodynamic therapy in treatment of recurrent squamous cell and basal cell carcinoma.
  • OBJECTIVES: A number of investigations have already been carried out to assess the effect of photodynamic therapy (PDT) on primary basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) lesions, but lack of investigations on recurrent lesions or lesions with treatment failure, prompted the authors to carry out this study.
  • The aim of the present study was to evaluate the efficacy of photodynamic therapy on recurrent BCC and SCC lesions on head and neck skin.
  • PATIENTS AND METHODS: A total of 30 patients, including 16 men and 14 women, were selected from patients with recurrent SCC and BCC who referred to Iran university ENT research center Rasool-e-Akram Hospital, Tehran-Iran, met the criteria and entered the study.
  • The final result of complete response rate in three years of follow up, demonstrated that 16 (64%) patients out of 25 were disease-free from recurrent BCC and SCC (Table 1).
  • DISCUSSION: The obtained data from the current study is supportive of the recommended treatment method of PDT as an effective, tolerable and less invasive treatment in patients with recurrent BCC and SCC carcinomas, particularly when cosmetic effects are an important consideration.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy


98. Rudolph J, Berl J, Hamm B, Klingebiel R: Magnetic resonance imaging findings of basal cell adenoma in Curschmann-Steinert myotonic dystrophy. Acta Radiol; 2006 Mar;47(2):205-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging findings of basal cell adenoma in Curschmann-Steinert myotonic dystrophy.
  • Myotonic dystrophy Curschmann Steinert is a common hereditary disorder that in some cases can be combined with cutaneous tumors, which is an association that is rarely described in the literature.
  • We present the magnetic resonance imaging in the unusual combination of a patient with known myotonic dystrophy and recurrent basal cell tumor.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma, Basal Cell / diagnosis. Head and Neck Neoplasms / diagnosis. Magnetic Resonance Imaging. Myotonic Dystrophy / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Myotonic dystrophy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604969.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


99. Nikitin AA, Andriukhina VV, Spiridonova NZ, Stuchilov VA, Kosiakov MN: [The treatment of primary and recurrent of basaliomas of head and neck soft and bony tissues]. Voen Med Zh; 2007 May;328(5):36-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The treatment of primary and recurrent of basaliomas of head and neck soft and bony tissues].
  • [MeSH-major] Bone Neoplasms / surgery. Carcinoma, Basal Cell / surgery. Cryosurgery / methods. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17726962.001).
  • [ISSN] 0026-9050
  • [Journal-full-title] Voenno-medit︠s︡inskiĭ zhurnal
  • [ISO-abbreviation] Voen Med Zh
  • [Language] rus
  • [Publication-type] Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


100. Ortonne N, Wechsler J, Bagot M, Grosshans E, Cribier B: Granuloma faciale: a clinicopathologic study of 66 patients. J Am Acad Dermatol; 2005 Dec;53(6):1002-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A clinical diagnosis of GF was made in only 10 cases; sarcoidosis, lymphoma, lupus, and basal cell carcinoma were the main differential diagnoses.
  • There was often an association of acute and chronic inflammatory patterns, suggesting that GF follows a chronic history with recurrent acute phases, rather than distinct successive acute and chronic stages.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16310061.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement